Lupus alpha Fonds

An investment fund subject to Luxembourg law

Sub-funds:

Lupus alpha Sustainable Smaller Euro Champions
Lupus alpha Smaller German Champions
Lupus alpha Micro Champions
Lupus alpha All Opportunities Fund
Lupus alpha Global Convertible Bonds

Audited Annual Report

for the period from 1 January 2024 to 31 December 2024

RCS: K-1492

The prospectus and the management regulations are only valid in conjunction with the most recent annual report and, if the reporting date of the latter is more than eight months ago, also with the most recent semi-annual report.

The prospectus, the KID (Key Information Document) and the respective annual and semi-annual reports are available free of charge at the registered office of the management company, the custodian and at the paying agents, the information agents and the distributors.

A list of changes in securities assets is freely available upon request by unitholders at the registered office of the management company and the German paying and information agent as well as the distributor.

Lupus alpha Fonds and its sub-funds are authorised for public distribution in the Federal Republic of Germany, the French Republic and the Republic of Austria.

Note:

The components of the annual report comply with the requirements of art. 151 para. 3 with reference to chapters I to IV of schedule B of the law of 17 December 2010.

Contents

| Management and administration | 4 |
|--|-----|
| Information for unitholders | 6 |
| Management report | 7 |
| Management report on risk management | .20 |
| Report of the réviseur d'entreprises agréé | .22 |
| Statement of Net Assets as of 31 December 2024 | .25 |
| Statement of Operations and Changes in Net Assets | .27 |
| Statistical Information | .29 |
| Notes to the Annual Report as of 31 December 2024 | .30 |
| Schedule of investments: | |
| Lupus alpha Fonds – Lupus alpha Sustainable Smaller Euro Champions | .43 |
| Lupus alpha Fonds – Lupus alpha Smaller German Champions | .46 |
| Lupus alpha Fonds – Lupus alpha Micro Champions | .49 |
| Lupus alpha Fonds – Lupus alpha All Opportunities Fund | .52 |
| Lupus alpha Fonds – Lupus alpha Global Convertible Bonds | .58 |
| Other information (unaudited) | .65 |

Management and administration

Management company Lupus alpha Investment GmbH

Speicherstraße 49-51

D-60327 Frankfurt am Main, Germany

Executive Board and mandates of theDr. Götz Albert
Executive Board
Managing Partner,

Lupus alpha Asset Management AG,

Frankfurt am Main

Michael Frick Managing Partner,

Lupus alpha Asset Management AG,

Frankfurt am Main

Ralf Lochmüller

CEO.

Lupus alpha Asset Management AG,

Frankfurt am Main/ Managing Director of Lupus alpha Holding GmbH,

Frankfurt am Main

Supervisory Board Chairman

Dr. Oleg De Lousanoff, lawyer and notary

Deputy Chairman

Dietrich Twietmeyer, Dipl. Agr. Ing.

Member

Dr. Helmut Wölfel, Legal counsel

Fund manager Lupus alpha Asset Management AG

Speicherstraße 49-51

D-60327 Frankfurt am Main, Germany

Depository, Central administration and

Registrar and transfer agent

J.P. Morgan SE - Luxembourg Branch European Bank and Business Centre

6, route de Trèves L-2633 Senningerberg

Grand Duchy of Luxembourg

Management and administration (continued)

Paying agents for Luxembourg:

J.P. Morgan SE – Luxembourg Branch European Bank and Business Center

6, route de Trèves L-2633 Senningerberg Grand Duchy of Luxembourg

for Austria:

UniCredit Bank Austria AG

Schottengasse 6-8 A-1010 Vienna, Austria

Information agents for Germany:

Lupus alpha Asset Management AG

Speicherstraße 49-51

D-60327 Frankfurt am Main, Germany

for Austria:

UniCredit Bank Austria AG

Schottengasse 6-8 A-1010 Vienna, Austria

Fund auditor KPMG Audit S.à r.l

39, Avenue John F. Kennedy

L-1855 Luxembourg

Management company's PricewaterhouseCoopers GmbH

auditor Wirtschaftsprüfungsgesellschaft Friedrich-Ebert-Anlage 35-37

60327 Frankfurt am Main, Germany

Distributor Lupus alpha Asset Management AG

Speicherstraße 49-51

D-60327 Frankfurt am Main, Germany

The management company may appoint other distributors to sell units of the fund in any other jurisdiction. Further information about any other distributors is contained in the specific section of the valid prospectus for the respective sub-fund.

Information for unitholders

The management company shall ensure that information intended for unitholders is published in an appropriate manner. The annually audited annual reports shall be published no later than four months after the end of each fiscal year and the unaudited semi-annual reports no later than two months after the end of the first half of the fiscal year. The reports are available to unitholders at the registered office of the management company, the custodian and the paying and information agents and the distributors.

The fiscal year of the fund shall begin on 1 January of each year and end on 31 December of the same year.

Issue and redemption prices may be obtained on each valuation date at the registered office of the management company, the custodian and from the paying agents, the information agents and the distributors.

Information for unitholders shall be published, in the electronic trade and corporate register in Luxembourg, the RESA ("Receuil élec-tronique des sociétés et associations") and on the website www.fundinfo.com or on the company's homepage www.lupusalpha.de. The management company may initiate additional publications.

Management report

Report of the Executive Board

Dear Investors,

The Executive Board of Lupus alpha Investment GmbH hereby presents the statement of accounts of the Lupus alpha Fund for the fiscal year from 1 January to 31 December 2024. In the past fiscal year, the following sub-funds were managed:

Lupus alpha Sustainable Smaller Euro Champions
Lupus alpha Smaller German Champions
Lupus alpha Micro Champions
Lupus alpha All Opportunities Fund
Lupus alpha Global Convertible Bonds

Investment strategy and investment objectives of the Sub-funds

"Performance is not created at a desk, but in discussions with companies and employees on site". This philosophy guides the investment decisions of the sub-funds. In addition to the selection of securities based on specific assessments of individual stocks, where company visits play a crucial role, a number of quantitative and qualitative criteria are also applied. The investment objective of each sub-fund is to outperform the relevant benchmark by selecting equities and convertible bonds.

Further details on the investment policy of the sub-funds can be found in the Notes.

Investment results

In 2023, when many experts wrongly predicted a severe recession in some of the world's major economies, global equities performed strongly. Again in 2024, few expected global equities to perform so strongly, and yet the S&P 500, for example, ended the year not far from its best annual performance of the 21st century. In particular, the US equity indices set one record after another, regularly hitting new highs, driven largely by the topic of artificial intelligence (AI) and the so-called "Magnificent Seven". Despite the outstanding performance of global equities, last year was not without its challenges. Some of the risk factors are emerging or intensifying geopolitical tensions, persistent inflation and the resulting uncertainty regarding central banks' interest rate policies, and an increasing concentration on a few large technology companies in the global equity indices.

Donald Trump's re-election as US president at the beginning of November determined the development of the capital markets in the last months of 2024. Tax cuts and deregulation are aimed at stimulating the US economy, financed primarily by tariffs on imports. This led to the continued rise in the US equity market, a strong US dollar and rising long-term interest rates on the bond market, despite the renewed interest rate cuts by the US Federal Reserve and the ECB. The flip side of the coin is reflected in the falling share prices in Europe and China, which have come under significant pressure in view of the planned US punitive tariffs and political upheaval (including the upcoming elections in Germany).

Overall, the global equity markets closed 2024 with significant price gains. The S&P 500 rose by +25.52%, the Euro Stoxx 50 by +11.29% and the Nikkei 225 by +21.27%. The DAX also recorded a gain of +18.85%. The Hang Seng, which posted a negative performance in 2023, ended 2024 with a positive performance of +22.79%.

Report of the Executive Board (continued)

Performance of selected indices:

| Index | 4th Quarter 2024 | since 29/12/2023 |
|-----------------------------|------------------|------------------|
| DAV | 2.020/ | 10.050/ |
| DAX | 3.02% | 18.85% |
| MDAX | -4.71% | -5.71% |
| SDAX | -3.18% | -1.78% |
| | 5.1370 | 117070 |
| TecDAX | 0.11% | 2.39% |
| Euro Stoxx 50 Net Return | -2.36% | 10.41% |
| Euro Stoxx TMI Return Index | -3.65% | -0.25% |

Report of the Executive Board (continued)


Lupus alpha Sustainable Smaller Euro Champions

In the first five months of 2024, the shares of small and medium-sized European companies achieved a positive performance of almost 10%. The main driver was the expectation of falling interest rates, which should serve both to encourage investment and to make refinancing cheaper for companies. However, most of these gains were given up over the rest of the year. This was due to the weak performance of the German economy and the political uncertainties in France, where new elections and the dispute over the 2025 state budget led to declining share prices.

In this context, Lupus alpha Sustainable Smaller Euro Champions C achieved a negative performance of -8.39% (unit class A: -8.85%) in 2024 and thus significantly underperformed the benchmark index EURO STOXX TMI Small EUR Net Return, which only lost -0.25%.

At the country level, the Sub-fund benefited most from stock selection in Austria and Belgium, while the largest detractors were Germany and Italy. In terms of sectors, the largest positive contributions to the Sub-fund came in construction and building materials, as well as real estate. On the other hand, the health care and banking sectors made the largest negative performance contributions.

Performance of Lupus alpha Sustainable Smaller Euro Champions C since launch until 31.12.2024: *




Benchmark: Euro Stoxx TMI Small Net Return

Launch date: 12/12/2001

^{*} Source: Lupus alpha; gross performance (BVI method): The gross performance takes into account all costs incurred at the fund level (e.g. management fees) and assumes that any distributions are reinvested. The costs incurred at the customer level, such as the front-end load and custody costs, are not taken into account. Please note: Past performance is not a reliable indicator of future performance.

Report of the Executive Board (continued)

Performance of Lupus alpha Sustainable Smaller Euro Champions A since launch until 31.12.2024: *



Benchmark: Euro Stoxx TMI Small Net Return

Launch date: 22/10/2001

Lupus alpha Smaller German Champions

Lupus alpha Smaller German Champions C achieved an absolute return of -8.71% in 2024 (unit class A: -9.17% and unit class CT: -8.71%), which corresponds to an underperformance of 5.03% (unit class A: 5.49% and unit class CT: 5.03%) compared to the benchmark (50% MDAX, 50% SDAX) with an absolute return of -3.68%. Since its launch, the sub-fund has generated a performance surplus of 864.29% in unit class C (unit class A: 747.80% and unit class CT: -26.04%) and it continues to significantly exceed its benchmark index (50% MDAX, 50% SDAX) with an outperformance of 388.34% (unit class A: 325.51%). Only in the unit class CT has the sub-fund underperformed by 3.00% since its launch. Since the launch of unit class C, the benchmark index (50% MDAX, 50% SDAX) has achieved a performance of 475.95% (since the launch of unit class A: 422.29% and since the launch of unit class CT: -23.04%).

In 2024, the world continued to face a number of crises, some of which originated in 2022 (war in Ukraine). But new crises also arose, such as Israel's fight against Hamas in the Gaza Strip from 7 October 2023. Added to this was the fact that the US entered the election campaign quite early and that investment restraint ultimately occurred there too, probably because people wanted to wait for the election result. Furthermore, companies in the US had apparently assumed that interest rates would fall, so they also reacted cautiously here in order to avoid investing too early. Since the US consumer was also cautious, presumably due to high inflation, the United States also experienced a slight recession. With China and Europe, the two other major world economic regions, also experiencing very weak economic growth, 2024 was ultimately a very weak economic year. In Europe, structural problems such as excessive bureaucracy and overregulation have increasingly come to the fore. In this environment, German companies also displayed deep uncertainty. From the outside, Germany, in particular its automotive industry, is viewed with concern. This is a prime example of how China has developed from being a very good customer to becoming a competitor. Added to this are the high energy prices in Germany, which represent a distinct disadvantage in international competition for energy-intensive local companies. International investors see this very negative top-down view of Germany and avoid investing in German SMEs, which they probably see most strongly represented by the MDAX and SDAX stocks. Instead, they are short selling these stocks, betting directly on declining share prices. With German investors also cautious, presumably due to the flows associated with these trends, these stocks were unable to turn in a positive performance for the year.

⁻

^{*} Source: Lupus alpha; gross performance (BVI method): The gross performance takes into account all costs incurred at the fund level (e.g. management fees) and assumes that any distributions are reinvested. The costs incurred at the customer level, such as the front-end load and custody costs, are not taken into account. Please note: Past performance is not a reliable indicator of future performance.

Report of the Executive Board (continued)


The solid performance of these companies, which was good despite everything, was overshadowed by some hefty price losses that supported the narrative of the fallen German Mittelstand. Against this backdrop, as in the previous year, it was difficult to engage in stock picking. As already described, good operational performance by companies were not rewarded (e.g. Fuchs SE, Dermapharm, IONOS Group, Cewe Group, Vossloh, Bilfinger), solid performers (such as Wacker Chemie, Jungheinrich, Jenoptik, Energiekontor) were even sold off, and negative performers were in some cases excessively penalised (such as Compugroup, PUMA, Hypoport, SGL Carbon).

We expect the situation on the German small and mid-cap market to brighten again after three very similar years. However, this would need to be supported by a general economic upturn. The poor consumer sentiment in Germany could possibly be brightened by an end to the war in Ukraine. The mood among companies could improve as a result of the election, in which most parties have now included economic issues on their programmes. In any case, valuations are cheap enough. Assuming that an average return of 7% per year is also possible with German SMEs, the reversion to the mean should result in a very high return potential.

Positive absolute and relative contributions came from stocks such as Siemens Energy, Redcare Pharmacy, Rheinmetall, Krones and Süss Microtech, all of which were overweight in the portfolio. Negative contributions resulted from the non-allocation or under-allocation of Auto1 Group, Delivery Hero, Morphosys and Hypoport, as well as stocks in the real estate sector, all of which had a very high weighting in the MDAX or SDAX and achieved a good absolute performance. Significant negative contributions due to overweighting came from Hugo Boss, Jenoptik, Vivoryon Therapeutics and Siltronic AG.

Report of the Executive Board (continued)


Performance of Lupus alpha Smaller German Champions C since launch until 31.12.2024:*



Benchmark: 50% MDAX + 50% SDAX

Launch date: 08/01/2002

Performance of Lupus alpha Smaller German Champions A since launch:



Benchmark: 50% MDAX + 50% SDAX

Launch date: 03/08/2001


_

^{*} Source: Lupus alpha; gross performance (BVI method): The gross performance takes into account all costs incurred at the fund level (e.g. management fees) and assumes that any distributions are reinvested. The costs incurred at the customer level, such as the front-end load and custody costs, are not taken into account. Please note: Past performance is not a reliable indicator of future performance.

[†] Source: Lupus alpha; gross performance (BVI method): The gross performance takes into account all costs incurred at the fund level (e.g. management fees) and assumes that any distributions are reinvested. The costs incurred at the customer level, such as the front-end load and custody costs, are not taken into account. Please note: Past performance is not a reliable indicator of future performance.

Report of the Executive Board (continued)

Performance of Lupus alpha Smaller German Champions CT since launch until 31.12.2024:



Benchmark: 50% MDAX + 50% SDAX

Launch date: 29/10/2021

Lupus alpha Micro Champions

Lupus alpha Micro Champions CAV achieved an absolute performance of -0.68% in 2024. It thus underperformed its benchmark index (MSCI Europe Micro Cap Net Total Return Index) by 2.73%; the benchmark gained +2.05% in the period under review. The A and C unit classes generated an absolute performance of -0.48% and +0.42%, respectively, underperforming the benchmark by 2.53% and 1.63%, respectively.

Key developments in 2024 included interest rate cuts by central banks in the Western world, macroeconomic challenges and significant political elections. At the beginning of the year, hopes of falling interest rates, supported by the decline in inflation, led to positive price developments on the markets. The European Central Bank then began the cycle of interest rate cuts in June, and since then rates were cut several times in 2024. Although this was initially seen as a strong catalyst for investment, the economic impetus it was expected to provide largely failed to materialise. The biggest challenge for companies was the continued uncertainty about the macroeconomic situation. Fear of an impending recession prevented medium-sized and large companies from expanding their investments. In addition, political uncertainties in Europe weighed on investor confidence. In Germany, the announcement of new elections led to uncertainty, while in France, political turmoil complicated the economic environment. At the same time, the re-election of Donald Trump in the US and the associated concerns about possible new import tariffs created uncertainty among European companies.


Overall, the performance of equities on the stock market varied greatly. While small and mid-cap stocks performed relatively in line with large-cap stocks, micro-cap stocks performed significantly worse, especially in the second half of the year. The primary driver remains the pronounced preference of market participants for high liquidity. At the same time, the micro-cap sector remains largely unaffected by strategic capital flows due to a lack of available ETFs. However, we are seeing increasing takeover activity on the part of strategic and private equity investors, who are deliberately exploiting the attractive valuation levels.

The sub-fund reduced its exposure to companies that would be particularly hard hit by a prolonged economic downturn. Furthermore, there was an above-average number of takeovers in the portfolio in 2024, which automatically led to corresponding divestments. Reallocations were made in companies with above-average cash flow strength that are benefiting from structural growth. We found these companies primarily in the technology sector. They include Baltic Classifieds Group, Planisware, Moltiply Group and Zeal Network. Exposure in Italy and Sweden was reduced regionally and increased in Germany and the UK. Germany is the largest individual country, followed by the United Kingdom and Sweden.

Report of the Executive Board (continued)

At the individual share level, the strongest positive contributions came from the Baltic Classifieds Group, Bloomsbury and the Coats Group. On the negative side were Amadeus Fire, Yougov and Nynomic.

Performance of Lupus alpha Micro Champions CAV since launch until 31.12.2024:*




Benchmark: MSCI Europe Micro Cap Net TR Index

Launch date: 16/06/2005

^{*} Source: Lupus alpha; gross performance (BVI method): The gross performance takes into account all costs incurred at the fund level (e.g. management fees) and assumes that any distributions are reinvested. The costs incurred at the customer level, such as the front-end load and custody costs, are not taken into account. Please note: Past performance is not a reliable indicator of future performance.

Report of the Executive Board (continued)


Performance of Lupus alpha Micro Champions (C) since launch until 31.12.2024:*



Benchmark: MSCI Europe Micro Cap Net TR Index

Launch date: 31/01/2019

Performance of Lupus alpha Micro Champions (A) since launch until 31.12.2024:



Benchmark: MSCI Europe Micro Cap Net TR Index

Launch date: 06/02/2019

^{*} Source: Lupus alpha; gross performance (BVI method): The gross performance takes into account all costs incurred at the fund level (e.g. management fees) and assumes that any distributions are reinvested. The costs incurred at the customer level, such as the front-end load and custody costs, are not taken into account. Please note: Past performance is not a reliable indicator of future performance.

Report of the Executive Board (continued)

Lupus alpha All Opportunities Fund

Lupus alpha All Opportunities Fund C ended the year 2024 with a negative performance of -6.92% (unit class A: -7.67%). Since its launch, the fund has thus achieved a performance of 155.19% (unit class A: 7.97%).


It was a difficult year for European small and mid-caps. In the second half of the year, many market participants had forecast a revival of business activity due to a low comparative base from the previous year. This did not materialise. By contrast, corporate earnings were weighed down by a significant increase in personnel costs. In addition to ongoing crises and tensions worldwide, political events in France and Germany also caused economic uncertainty in Europe.

In the first quarter, the fund lost disproportionately to the market because three larger individual investments lost significant value for company-specific reasons. In the period that followed, the fund developed in line with the general conditions.

The Lupus alpha All Opportunities Fund is designed to cushion the market against major fluctuations and not to carry the full risk of a long-only strategy. To this end, the fund also uses futures for hedging purposes. Since the futures used are more mid- and large-cap heavy, this results in a slight imbalance.

The additional negative impact of the outperformance of large caps versus small caps was very pronounced in 2024 compared to other years.

Performance of Lupus alpha All Opportunities Fund (C) since launch until 31.12.2024: *




Benchmark: none Launch date: 21/01/2008

_

^{*} Source: Lupus alpha; gross performance (BVI method): The gross performance takes into account all costs incurred at the fund level (e.g. management fees) and assumes that any distributions are reinvested. The costs incurred at the customer level, such as the front-end load and custody costs, are not taken into account. Please note: Past performance is not a reliable indicator of future performance.

Report of the Executive Board (continued)

Performance of Lupus alpha All Opportunities Fund (A) since launch until 31.12.2024: *



Benchmark: none Launch date: 31/05/2019

Lupus alpha Global Convertible Bonds

Lupus alpha Global Convertible Bonds posted a gain of 4.8% for the 2024 reporting period. Similar to the development in the previous year, price gains were achieved particularly in the second half of the year. There was support from the interest rate side, but above all from the underlying equities. The central banks in the eurozone and the US have begun to lower the key interest rates in several steps in the face of declining inflation data and a weakening of economic development (especially in the eurozone). This interest rate trend provided relief for the shares of high-growth small and mid-cap companies that typically underlie convertible bonds (keyword: discounted cash flows). While this development is only just beginning to emerge in Europe, and the market continues to be weighed down by economic and political uncertainties, the US market recovered significantly following the re-election of Donald Trump as president. The main reason for the recovery is the expectations of stimuli for the (US) economy in the form of tax cuts and deregulation.

In general, convertible bonds remain an effective way of investing in promising growth companies whose share prices may fluctuate considerably, while significantly reducing risk and capturing upside potential. In addition, convertible bond issuers are usually not the highly capitalised stock corporations that are heavily weighted in the well-known indices, which provides additional diversification from an investor's perspective. As in previous years, the portfolio management team took advantage of opportunities arising from market fluctuations and the primary market in the global convertible bond universe.


Accordingly, the Lupus alpha Global Convertible Bonds Sub-fund had an equity delta of around 53% at the end of the reporting period, i.e. in the medium and balanced range where the strengths of the asset class are most pronounced (convexity). As at the reporting date, 62% of all individual stocks were in the balanced area (equity delta of 30-60%) and thus in the ideal convex space. The average rating of the sub-fund is BBB-. Very weak credits were still avoided, so we continued to have no credit defaults. The interest rate sensitivity remained structurally low with a PV01 of 1.7 in Lupus alpha Global Convertible Bonds. Regionally, the focus remained on the developed markets, particularly the US. In terms of sectors, the investment strategy continues to focus on growth stocks. Accordingly, IT and consumer discretionary were the top-weighted sectors alongside industrials as at the reporting date.

In the 2024 fiscal year, the performance of the Lupus alpha Global Convertible Bonds C Sub-fund was 4.76% (benchmark Refinitiv Global Focus Hedged Convertible Bond Index (EUR) 6.90%). Unit class A achieved a performance of 4.13% in the calendar year 2024.

^{*} Source: Lupus alpha; gross performance (BVI method): The gross performance takes into account all costs incurred at the fund level (e.g. management fees) and assumes that any distributions are reinvested. The costs incurred at the customer level, such as the front-end load and custody costs, are not taken into account. Please note: Past performance is not a reliable indicator of future performance.

Report of the Executive Board (continued)

Performance of Lupus alpha Global Convertible Bonds (C hedged) since launch until 31.12.2024: *




Benchmark: Refinitiv Global Focus Hedged Convertible Bond Index (EUR)

Launch date: 06/02/2017

^{*} Source: Lupus alpha; gross performance (BVI method): The gross performance takes into account all costs incurred at the fund level (e.g. management fees) and assumes that any distributions are reinvested. The costs incurred at the customer level, such as the front-end load and custody costs, are not taken into account. Please note: Past performance is not a reliable indicator of future performance.

Report of the Executive Board (continued)

Performance of Lupus alpha Global Convertible Bonds (A hedged) since launch until 31.12.2024: *



Benchmark: Refinitiv Global Focus Hedged Convertible Bond Index (EUR)

Launch date: 16/01/2018

Luxembourg, April 2025

Lupus alpha Investment GmbH

Source: Lupus alpha; gross performance (BVI method): The gross performance takes into account all costs incurred at the fund level (e.g. management fees) and assumes that any distributions are reinvested. The costs incurred at the customer level, such as the front-end load and custody costs, are not taken into account. Please note: Past performance is not a reliable indicator of future performance.

Management report on risk management

Presentation of Value at Risk (VaR) ratios and leverage in accordance with regulations in force in Luxembourg:

General

The management company uses a risk management process that allows for monitoring of the risk positions of the portfolios of the managed funds at all times. In accordance with the law of 17 December 2010 and the applicable regulations of the Commission de Surveillance du Secteur Financier ("CSSF"), the management company reports on the risk management process at regular intervals. The management company shall ensure that, on the basis of appropriate methods, the overall risk associated with derivatives does not exceed the net asset value.

Value at Risk (VaR) approach

The management company uses VaR (Value at Risk = maximum loss that will not be exceeded with a certain probability, defined by the confidence level, during a certain period) to monitor the risks of the sub-funds. To calculate the VaR, 10,000 Monte Carlo simulations are carried out per fund on the basis of a 2-year price history. The VaR is calculated daily on the basis of all positions of the sub-fund with a confidence level of 99 % and a holding period of one day.

If a benchmark (index or composite index) exists for the relevant sub-fund that adequately reflects the risk structure of the sub-fund, the relative VaR approach will be used. If no suitable benchmark is available due to the investment concept, the absolute VaR approach shall be applied.

The VaR in the case of the relative VaR approach may never exceed twice the VaR of the benchmark. In the absolute VaR approach, the VaR may never exceed 20 % based on a holding period of 20 days and a confidence level of 99 %.

The minimum, maximum and average VaR for the period under review from 1 January 2024 to 31 December 2024 were as follows:

Sub-fund according to the relative VaR approach

 Minimum VaR (99.1)
 1.9401%

 Average VaR (99.1)
 2.1908%

 Maximum VaR (99.1)
 2.6056%

Benchmark 100% EURO STOXX (r) TMI SMALL EUR Net

Lupus alpha Smaller German Champions

 Minimum VaR (99.1)
 2.1388%

 Average VaR (99.1)
 2.4107%

 Maximum VaR (99.1)
 2.7419%

Benchmark 50% MDAX / 50% SDAX

Lupus alpha Micro Champions

Minimum VaR (99.1) 1.6361% Average VaR (99.1) 1.8676% Maximum VaR (99.1) 2.3207%

Benchmark 100% MSCI Europe Micro Cap Net Total Return (EUR)

Lupus alpha Global Convertible Bonds

Minimum VaR (99.1) 0.9283% Average VaR (99.1) 1.1122% Maximum VaR (99.1) 1.4349%

Benchmark 50% MSCI World Net Return EUR

50% BofA Merril Lynch Global Corporate & High Yield Index EUR

Lupus alpha All Opportunities

Minimum VaR (99.1) 0.7947% Average VaR (99.1) 1.0593% Maximum VaR (99.1) 1.5926%

Benchmark Absolute Var approach

Presentation of Value at Risk (VaR) ratios and leverage in accordance with regulations in force in Luxembourg (continued):

Methodological limits of the Value at Risk approach

The VaR method attempts to measure the market risk of a portfolio as accurately as possible using mathematical, statistical methods, but is subject to certain limitations. VaR is based on a model of risk factors. Risk factors may be absent, there may be poorly defined risk factors or there may be risk factors that are not predictable. This may result in the risk model not adequately reflecting future risk. In addition, the returns of the various risk factors may not be directly observable on the market and must then be estimated using statistical techniques. Given that these estimates of risk factors may be imprecise, VaR may not accurately reflect future risk.

Leverage

The management company complies with the principles set out in Box 24 of ESMA Directive 10-788. For calculating leverage, the commitment approach as described in CSSF circular 11/512 is used.

If the VaR approach is chosen for calculating and monitoring the risk, the leverage effect of derivative exposure must also be reported in accordance with CSSF circular 11/512. For this purpose, the ratio between market exposure from the use of derivative financial instruments in excess of the sub-fund's assets and the sub-fund's assets is calculated. The expected leverage, which is also stated in the Lupus alpha Fonds prospectus, may be exceeded as well as fallen short of.

It is pointed out that a leverage calculated in this way has only limited informative value with regard to the market risks actually assumed. Market risks are quantified using the value-at-risk (VaR) approach.

The leverage (nominal value method) of the sub-funds from 1 January 2024 to 31 December 2024 was as follows:

| Lupus alpha Sustainable Smaller Euro Champions | | | | | |
|--|------|--|--|--|--|
| Minimum leverage: | 0.00 | | | | |
| Average leverage: | 0.00 | | | | |
| Maximum leverage: | 0.00 | | | | |
| Expected leverage: | 0.00 | | | | |
| | | | | | |
| <u>Lupus alpha Smaller German Champions</u> | | | | | |
| Minimum leverage: | 0.00 | | | | |
| Average leverage: | 0.00 | | | | |
| Maximum leverage: | 0.00 | | | | |
| Expected leverage: | 0.00 | | | | |
| | | | | | |
| Lupus alpha Micro Champions | | | | | |
| Minimum leverage: | 0.00 | | | | |
| Average leverage: | 0.00 | | | | |
| Maximum leverage: | 0.00 | | | | |
| Expected leverage: | 0.00 | | | | |
| | | | | | |
| Lupus alpha All Opportunities | | | | | |
| Minimum leverage: | 0.40 | | | | |
| Average leverage: | 0.60 | | | | |
| Maximum leverage: | 0.80 | | | | |
| Expected leverage: | 1.00 | | | | |
| | | | | | |
| Lupus alpha Global Convertible Bonds | | | | | |
| Minimum leverage: | 1.10 | | | | |
| Average leverage: | 1.10 | | | | |
| Maximum leverage: | 1.20 | | | | |
| Expected leverage: | 2.00 | | | | |
| - - | | | | | |

Only the signed version of the financial statements has been audited by the réviseur d'entreprises agréé and the audit report only refers to this version. In any case of doubt the original signed document shall prevail.

To the Unitholders of Lupus alpha Fonds Speicherstraße 49-51 D-60327 Frankfurt am Main

REPORT OF THE REVISEUR D'ENTREPRISES AGREE

Report on the audit of the financial statements

Opinion

We have audited the financial statements of Lupus alpha Fonds and each of its sub-funds ("the Fund"), which comprise the statement of net assets and the schedule of investments and other net assets as at 31 December 2024 and the statement of operations and the statement of changes in net assets for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of Lupus alpha Fonds and each of its sub-funds as at 31 December 2024, and of the results of their operations and changes in their net assets for the year then ended in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the financial statements.

Basis for opinion

We conducted our audit in accordance with the Law of 23 July 2016 on the audit profession ("Law of 23 July 2016") and with International Standards on Auditing ("ISAs") as adopted for Luxembourg by the Commission de Surveillance du Secteur Financier ("CSSF"). Our responsibilities under the Law of 23 July 2016 and ISAs as adopted for Luxembourg by the CSSF are further described in the « Responsibilities of "réviseur d'entreprises agréé" for the audit of the financial statements » section of our report. We are also independent of the Fund in accordance with the International Code of Ethics for Professional Accountants, including International Independence Standards, issued by the International Ethics Standards Board for Accountants ("IESBA Code") as adopted for Luxembourg by the CSSF together with the ethical requirements that are relevant to our audit of the financial statements, and have fulfilled our other ethical responsibilities under those ethical requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other information

The Board of the Fund's Management Company is responsible for the other information. The other information comprises the information stated in the annual report but does not include the financial statements and our report of the "réviseur d'entreprises agréé" thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

Only the signed version of the financial statements has been audited by the réviseur d'entreprises agréé and the audit report only refers to this version. In any case of doubt the original signed document shall prevail.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report this fact. We have nothing to report in this regard.

Responsibilities of the Board of Managers of the Fund's Management Company and Those Charged with Governance for the financial statements

The Board of Managers of the Fund's Management Company is responsible for the preparation and fair presentation of these financial statements in accordance with Luxembourg legal and regulatory requirements relating to the preparation and presentation of the financial statements, and for such internal control as the Board of Managers of the Fund's Management Company determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Managers of the Fund's Management Company is responsible for assessing the Fund's and each of its sub-funds' ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Managers of the Fund's Management Company either intends to liquidate the Fund or any of its sub-funds or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Fund's financial reporting process.

Responsibilities of the "réviseur d'entreprises agréé" for the audit of the financial statements

The objectives of our audit are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a report of the "réviseur d'entreprises agréé" that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Law of 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with the Law of 23 July 2016 and with ISAs as adopted for Luxembourg by the CSSF, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit
 procedures that are appropriate in the circumstances, but not for the purpose of expressing
 an opinion on the effectiveness of the Fund's internal control.

Only the signed version of the financial statements has been audited by the réviseur d'entreprises agréé and the audit report only refers to this version. In any case of doubt the original signed document shall prevail.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Managers of the Fund's Management Company.
- Conclude on the appropriateness of the Board of Managers of the Fund's Management Company use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Fund's or any of its sub-funds' ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our report of the "réviseur d'entreprises agréé" to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our report of the "réviseur d'entreprises agréé". However, future events or conditions may cause the Fund or any of its sub-funds to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Luxembourg, 15 April 2025

KPMG Audit S.à r.l. Cabinet de révision agréé

Jan Jansen

Lupus alpha Fonds Annual Report for the period from 1 January 2024 to 31 December 2024

Statement of Net Assets as of 31 December 2024

| | Lupus alpha Sustainable Smaller Euro Champions EUR | Lupus alpha Smaller German Champions EUR | Lupus alpha Micro Champions EUR | Lupus alpha All Opportunities Fund EUR |
|--|---|---|--|---|
| Assets | | | | |
| Investments in securities at cost | 54,615,801 | 425,455,172 | 105,234,747 | 63,083,015 |
| Unrealised gain/(loss) | (1,025,057) | 16,582,588 | 8,014,009 | (7,216,147) |
| Investments in securities at market value | 53,590,744 | 442,037,760 | 113,248,756 | 55,866,868 |
| Cash at bank and at brokers | 1,191,328 | 12,498,019 | 3,110,975 | 7,913,305 |
| Receivables on subscriptions | 316 | 50,631 | 99,092 | 250 |
| Receivables on investments sold | 13,654 | 3,197,507 | 202,273 | _ |
| Dividends receivable | _ | _ | 25,775 | _ |
| Dividends receivable on contracts for difference | _ | _ | _ | 2,116 |
| Interest receivable on contracts for difference | _ | _ | _ | 49,998 |
| Tax reclaims receivable | 72,751 | 685,014 | 64,836 | 47,474 |
| Fee waiver receivable | 113,596 | 306,750 | 173,010 | 99,179 |
| Options purchased contracts at fair value | _ | _ | _ | _ |
| Unrealised gain on financial futures contracts | _ | _ | _ | 313,925 |
| Contracts for difference at fair value | _ | _ | _ | 273,082 |
| Total assets | 54,982,389 | 458,775,681 | 116,924,717 | 64,566,197 |
| Liabilities | | | | |
| Bank overdrafts | _ | _ | _ | 506,159 |
| Payables on redemptions | 4,964 | 812,444 | 74,917 | 1,978 |
| Payables on investments purchased | _ | 77,777 | _ | _ |
| Interest payable | _ | _ | _ | 7,162 |
| Management fees payable | 58,447 | 583,107 | 142,563 | 57,933 |
| Unrealised loss on forward currency exchange contracts | - | _ | _ | _ |
| Contracts for difference at fair value | _ | _ | _ | 270,914 |
| Other liabilities | 42,064 | 186,452 | 84,880 | 43,882 |
| Total liabilities | 105,475 | 1,659,780 | 302,360 | 888,028 |
| Total net assets | 54,876,914 | 457,115,901 | 116,622,357 | 63,678,169 |

Lupus alpha Fonds Annual Report for the period from 1 January 2024 to 31 December 2024

Statement of Net Assets as of 31 December 2024 (continued)

| | Lupus alpha Global Convertible Bonds EUR | Lupus alpha Fonds Combined TOTAL EUR |
|--|---|---|
| Assets | | |
| Investments in securities at cost | 29,460,766 | 677,849,501 |
| Unrealised gain/(loss) | 1,904,118 | 18,259,511 |
| Investments in securities at market value | 31,364,884 | 696,109,012 |
| Cash at bank and at brokers | 1,295,945 | 26,009,572 |
| Receivables on subscriptions | _ | 150,289 |
| Receivables on investments sold | _ | 3,413,434 |
| Dividends receivable | _ | 25,775 |
| Dividends receivable on contracts for difference | _ | 2,116 |
| Interest receivable | 112,664 | 162,662 |
| Tax reclaims receivable | 2,176 | 872,251 |
| Fee waiver receivable | _ | 692,535 |
| Options purchased contracts at fair value | 84,819 | 84,819 |
| Unrealised gain on financial futures contracts | _ | 313,925 |
| Contracts for difference at fair value | | 273,082 |
| Total assets | 32,860,488 | 728,109,472 |
| Liabilities | | |
| Bank overdrafts | _ | 506,159 |
| Payables on redemptions | 518,304 | 1,412,607 |
| Payables on investments purchased | _ | 77,777 |
| Interest payable on contracts for difference | _ | 7,162 |
| Management fees payable | 17,367 | 859,417 |
| Unrealised loss on forward currency exchange contracts | 547,614 | 547,614 |
| Contracts for difference at fair value | _ | 270,914 |
| Other liabilities | 1,896 | 359,174 |
| Total liabilities | 1,085,181 | 4,040,824 |
| Total net assets | 31,775,307 | 724,068,648 |

The consolidated statement of net assets result from the total sum of the respective values of all sub-funds. Cross-fund investments (where a sub-fund has invested in another sub-fund of the fund) and the related cross-fund accounts/balances have not been eliminated for the purposes of presenting the consolidated results. As of 31 December 2024, cross-fund investments represented 0.00% of consolidated net assets.

Lupus alpha Fonds Annual Report for the period from 1 January 2024 to 31 December 2024

Statement of Operations and Changes in Net Assets

| | Lupus alpha Sustainable Smaller Euro Champions EUR | Lupus alpha Smaller German Champions EUR | Lupus alpha Micro Champions EUR | Lupus alpha All Opportunities Fund EUR |
|--|---|---|--|---|
| Net assets at the beginning of the year | 77,724,765 | 681,990,563 | 141,987,935 | 79,104,311 |
| Income | | | | |
| Dividend income, net of withholding taxes | 2,239,203 | 9,658,896 | 2,392,702 | 1,423,739 |
| Interest income from investments, net of | | | | |
| withholding taxes | _ | _ | _ | 251,268 |
| Dividend income on contracts for difference | _ | _ | = | 189,205 |
| Bank interest | 78,520 | 606,595 | 190,905 | 181,362 |
| Other income | | | | 30,754 |
| Total income | 2,317,723 | 10,265,491 | 2,583,607 | 2,076,328 |
| Expenses | | | | |
| Management fees | 908,917 | 8,089,071 | 1,878,209 | 742,776 |
| Depositary fees | 3,275 | , , , <u>–</u> | | , |
| Administrative fees | 31,745 | 141,114 | 47,814 | 30,035 |
| Audit fees | 4,935 | 40,019 | 8,452 | 4,635 |
| Professional fees | 420 | 3,271 | 702 | 360 |
| Dividend expense on contracts for difference | _ | _ | _ | 168,056 |
| Interest expense on contracts for difference | _ | _ | _ | 137,775 |
| Other Operating expenses | 98,433 | 654,357 | 164,103 | 99,111 |
| Total expenses | 1,047,725 | 8,927,832 | 2,099,280 | 1,182,748 |
| Not in the second in the secon | 1 2 (0 000 | 1 227 (50 | 494 227 | 902 590 |
| Net investment income/(loss) | 1,269,998 | 1,337,659 | 484,327 | 893,580 |
| Net realised gain/(loss) on: | | | | |
| Sale of investments | (73,547) | (36,324,014) | 1,247,652 | 3,421,539 |
| Options contracts | _ | _ | _ | (575,141) |
| Financial futures contracts | _ | _ | _ | (1,689,613) |
| Forward currency exchange contracts | _ | _ | 4,087 | _ |
| Contracts for difference | _ | _ | - | (1,540,863) |
| Currency exchange | 462 | 1,513 | (14,793) | 31,397 |
| Net realised gain/(loss) for the year | (73,085) | (36,322,501) | 1,236,946 | (352,681) |
| Net change in unrealised | | | | |
| appreciation/(depreciation) on: | | | | |
| Investments | (7,874,692) | (15,665,165) | (1,972,666) | (5,757,913) |
| Options contracts | _ | _ | _ | 231,103 |
| Financial futures contracts | _ | _ | _ | 144,425 |
| Forward currency exchange contracts | _ | _ | = | - |
| Contracts for difference | _ | _ | = | (530,901) |
| Currency exchange | 1 | 6 | 982 | (228) |
| Net change in unrealised | | | | |
| appreciation/(depreciation) for the year | (7,874,691) | (15,665,159) | (1,971,684) | (5,913,514) |
| Increase/(decrease) in net assets as a result of | | | | |
| operations | (6,677,778) | (50,650,001) | (250,411) | (5,372,615) |
| | | | | |
| Subscriptions | 20,725,021 | 48,968,322 | 9,770,367 | 5,143,399 |
| Redemptions | (36,895,094) | (223,192,983) | (32,930,152) | (15,196,926) |
| Increase/(decrease) in net assets as a result of | , <u>,</u> | | | , |
| movements in share capital | (16,170,073) | (174,224,661) | (23,159,785) | (10,053,527) |
| Dividend distributions | _ | | (1,955,382) | |
| Net assets at the end of the year | 54,876,914 | 457,115,901 | 116,622,357 | 63,678,169 |

Lupus alpha Fonds Annual Report for the period from 1 January 2024 to 31 December 2024

Statement of Operations and Changes in Net Assets (continued)

| | Lupus alpha Global Convertible Bonds EUR | Lupus alpha Fonds Combined TOTAL EUR |
|--|---|---|
| Net assets at the beginning of the year | 38,271,628 | 1,019,079,202 |
| Income | | |
| Dividend income, net of withholding taxes | 8,591 | 15,723,131 |
| Interest income from investments, net of | | |
| withholding taxes | 477,972 | 729,240 |
| Dividend income on contracts for difference | _ | 189,205 |
| Bank interest | 27,480 | 1,084,862 |
| Other income | - | 30,754 |
| Total income | 514,043 | 17,757,192 |
| Expenses | | |
| Management fees | 209,059 | 11,812,394 |
| Depositary fees | | 3,275 |
| Administrative fees | 19,932 | 270,640 |
| Audit fees | 2,282 | 60,323 |
| Professional fees | 183 | 4,936 |
| Dividend expense on contracts for difference | _ | 168,056 |
| Interest expense on contracts for difference | = | 137,775 |
| Other Operating expenses | 31,541 | 1,047,545 |
| Total expenses | 262,997 | 13,520,582 |
| Not investment in some/(less) | 251,046 | 4,236,610 |
| Net investment income/(loss) | 251,040 | 4,230,010 |
| Net realised gain/(loss) on: | | |
| Sale of investments | 1,533,350 | (30,195,020) |
| Options contracts | 22,177 | (552,964) |
| Financial futures contracts | | (1,689,613) |
| Forward currency exchange contracts | (1,066,977) | (1,062,890) |
| Contracts for difference | - | (1,540,863) |
| Currency exchange | 153,510 | 172,089 |
| Net realised gain/(loss) for the year | 642,060 | (34,869,261) |
| Net change in unrealised | | |
| appreciation/(depreciation) on: | | |
| Investments | 1,687,564 | (29,582,872) |
| Options contracts | (120,333) | 110,770 |
| Financial futures contracts | = | 144,425 |
| Forward currency exchange contracts | (1,078,291) | (1,078,291) |
| Contracts for difference | - | (530,901) |
| Currency exchange | (7,768) | (7,007) |
| Net change in unrealised | | |
| appreciation/(depreciation) for the year | 481,172 | (30,943,876) |
| Increase/(decrease) in net assets as a result of | | |
| operations | 1,374,278 | (61,576,527) |
| Subscriptions | 1,749,533 | 86,356,642 |
| Redemptions | (9,115,664) | (317,330,819) |
| Increase/(decrease) in net assets as a result of | (7,113,007) | (317,330,819) |
| movements in share capital | (7,366,131) | (230,974,177) |
| Dividend distributions | (504,468) | (2,459,850) |
| | . , , | , i i i |
| Net assets at the end of the year | 31,775,307 | 724,068,648 |

The consolidated statement of net assets result from the total sum of the respective values of all sub-funds. Cross-fund investments (where a sub-fund has invested in another sub-fund of the fund) and the related cross-fund accounts/balances have not been eliminated for the purposes of presenting the consolidated results. As of 31 December 2024, cross-fund investments represented 0.00% of consolidated net assets.

Lupus alpha Fonds Annual Report for the period from 1 January 2024 to 31 December 2024

Statistical Information

| | Units outstanding | NAV per unit | NAV per unit | NAV per unit |
|--------------------------------------|-------------------------|-------------------------|-------------------------|-------------------------|
| | as at | as at | as at | as at |
| | 31 December 2024 | 31 December 2024 | 31 December 2023 | 31 December 2022 |
| Lupus alpha Sustainable Smaller Euro | | | | |
| Champions | | | | |
| Class A | 86,042 | 272.77 | 299.24 | 253.52 |
| Class C | 99,870 | 314.48 | 343.28 | 289.62 |
| Total net assets in EUR | | 54,876,914 | 77,724,765 | 57,177,061 |
| Lupus alpha Smaller German Champions | | | | |
| Class A | 912,732 | 415.10 | 457.00 | 419.00 |
| Class C | 133,822 | 474.77 | 520.08 | 474.42 |
| Class CT | 397,741 | 36.98 | 40.51 | 36.34 |
| Total net assets in EUR | | 457,115,901 | 681,990,563 | 609,174,394 |
| Lupus alpha Micro Champions | | | | |
| Class A | 146,188 | 142.04 | 145.05 | 153.20 |
| Class C | 389,196 | 150.90 | 152.69 | 159.82 |
| Class CAV | 186,910 | 198.64 | 203.25 | 215.10 |
| Total net assets in EUR | | 116,622,357 | 141,987,935 | 197,166,829 |
| Lupus alpha All Opportunities Fund | | | | |
| Class A | 27,318 | 106.04 | 114.85 | 106.43 |
| Class C | 484,932 | 125.34 | 134.66 | 123.79 |
| Total net assets in EUR | | 63,678,169 | 79,104,311 | 97,257,275 |
| Lupus alpha Global Convertible Bonds | | | | |
| Class A hedged | 9,967 | 96.64 | 94.23 | 91.34 |
| Class C hedged | 286,742 | 107.46 | 104.14 | 100.34 |
| Total net assets in EUR | | 31,775,307 | 38,271,628 | 52,814,508 |

Notes to the Annual Report (as of 31 December 2024)

Note 1 – General

Lupus alpha Fonds ("the fund") was launched on the initiative of Lupus alpha Investment S.A. (liquidated).

Lupus alpha Fonds was transferred to Lupus alpha Investment GmbH, registered office Speicherstraße 49-51, D- 60327 Frankfurt am Main, with effect from 1 January 2020.

The fund was first established as an investment fund (fonds commun de placement) pursuant to Part 1 of the Luxembourg Law of 30 March 1988 on Undertakings for Collective Investment ("the Law of 30 March 1988") by Lupus alpha Investment S.A. (liquidated) on 13 December 2000. On 1 July 2011, the fund was adapted to the Luxembourg Law of 17 December 2010, Part I on Undertakings for Collective Investment ("the Law of 17 December 2010"). It offers investors the opportunity to become co-owners of a fund under Luxembourg law.

The fund is managed by Lupus alpha Investment GmbH in accordance with the fund's management regulations, which form an integral part of the prospectus. The management regulations were first published in the Mémorial C, Recueil des Sociétés et Associations ("Mémorial") on 25 January 2001. Changes to the management regulations last entered into force on 19 January 2024 and have been filed with the Trade and Companies Register in Luxembourg. A reference to this filing was published in RESA ("Recueil électronique des sociétés et associations") on 8 January 2024.

The fund's management company was founded on 15 July 2001 as Lupus alpha Investment GmbH (formerly Lupus alpha Kapitalanlagegesellschaft mbH), registered office Speicherstraße 49-51, D-60327 Frankfurt am Main, Germany.

The fund's management company has the legal form of a Private Limited Company (GmbH), has a permit as a management company according to the German Capital Investment Code (KAGB).

The fund's management company has appointed Lupus alpha Asset Management AG, (the "fund manager") to manage Lupus alpha Fonds. Remuneration paid to the fund manager is described in the management regulations under article 15 "fund charges".

Lupus alpha Asset Management AG, Speicherstraße 49-51, D-60327 Frankfurt am Main, Germany, is an investment company under German law and is active in the field of asset management, investment advice, fund management and investments. Lupus alpha Asset Management AG was founded on 9 August 1996 and is registered in the Frankfurt commercial register under the number HRB-90649. The company's share capital as well as its equity capital according to article 10 of the German Banking Act (Kreditwesengesetz) amounted to 500,000 EUR on 31 December 2006. The share capital was fully subscribed and paid in.

The fund is a legally dependent joint asset of all unitholders which is managed by the management company in its own name but for the account of the unitholders. In doing so, the management company invests the deposited money in its own name for the collective account of the unitholders, observing the principle of risk spreading. The money deposited and the assets acquired with it form the fund assets, which are managed separately by the management company. The unitholders participate in the fund assets in the amount of their units.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 1 – General (continued)

The following sub-funds are currently offered to investors under one and the same fund:

• Lupus alpha Fonds – Lupus alpha Sustainable Smaller Euro Champions

The objective of the investment policy is to achieve the highest possible increase in value. At least 51% of the value of the subfund is invested in small and medium-sized European companies (small and mid-caps), such as those in the EURO STOXX® TMI Small EUR Net Return Index (an index of STOXX Limited, Zurich), which are admitted to official trading on a stock exchange or admitted to or included in another organised market and which are not units in investment funds. Due to investment policy interests, European large caps which are admitted to official trading on a stock exchange or admitted to or included in another organised market and which are not units in investment funds may also be taken into account.

The sub-fund promotes environmental and/or social features but does not target sustainable investments. The sub-fund considers risks related to sustainability when making investment decisions. The fund manager examines the sustainability risks arising for the sub-fund in compliance with the sub-fund's investment policy. Sustainability risks may have a significant impact on the value of the fund's investments in the medium to long term. As deterioration in ESG scores as well as emerging controversies surrounding target companies in which the sub-fund invests may already have a negative impact on a sub-fund investment in the short or medium term, the fund manager pays particular attention to these ESG criteria and changes over time. The sub-fund's assets are only invested in convertible bonds that are selected according to the principles of sustainability. To this end, issuers are analyzed and classified according to environmental, social and governance criteria. This includes, among other things, the issuers' environmental management, their social standards and corporate governance, as well as their product portfolio. This may lead to the exclusion of companies from certain sectors (such as controversial weapons, fossil fuels, nuclear energy). Likewise, investments should not be made in companies that violate human and labour rights or that are involved in corruption. In addition, companies may be selected through the sustainability analysis depending on the contribution they make to the fulfilment of the Sustainable Development Goals of the United Nations.

Information about environmental and/or social characteristics advertised by this sub-fund and about how the Principal Adverse Impacts (PAI) of investment decisions are taken into consideration can be found in the Downloads section of the Company's website under ESG Methodik: https://www.lupusalpha.de/downloads// and at https://www.lupusalpha.de/fonds/ in the Lupus alpha Sustainable Smaller Euro Champions section under RTS appendix.

The management company has decided to issue different unit classes for the sub-fund. Investors therefore have a choice between unit classes "A" and "C". The investment policy of both unit classes is identical to that of the sub-fund as a whole, the only differences being the charges incurred for these unit classes and the minimum investment amount.

Units in the sub-fund will be issued in distributing form only for both unit classes. Capital gains, other income and interest not intended to cover costs, dividends and income from lending and repurchase transactions may be used for distribution.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 1 – General (continued)

• Lupus alpha Fonds – Lupus alpha Smaller German Champions

The objective of the investment policy is to achieve the highest possible growth in value. At least 51% of the value of the subfund is invested in small and medium-sized European companies (small and mid-caps), such as those in the MDAX® Performance-Index or the SDAX® Performance-Index, as well as in stocks of the Technology All Share Index (indices of Deutsche Börse AG), which are admitted to official trading on a stock exchange or admitted to or included in another organised market and which are not units in investment funds. Due to investment policy interests, investments may also be made in European large caps that are admitted to official trading on a stock exchange or admitted to or included in another organised market and which are not units in investment funds.

The sub-fund considers risks related to sustainability when making investment decisions. The fund manager examines the ESG risks arising for the sub-fund taking into account the various requirements of the sub-fund's investment policy. In this process, securities or their issuers are analysed for sustainability risks using ESG criteria before any investment decision is made. ESG information and ESG criteria are taken into account for investment decisions, but are not decisive, so that the fund management may invest in securities and issuers that do not follow ESG criteria.

The investments underlying this sub-fund do not take into account the EU criteria for environmentally sustainable economic activities.

The management company has decided to issue different unit classes for the sub-fund. Investors therefore have a choice between unit classes "A", "C", "CT" and "CAV". The investment policy of the unit classes is identical to that of the sub-fund as a whole, the only differences being the charges incurred for these unit classes and the minimum investment amount.

Units in the sub-fund will be issued in distributing and accumulating form. Capital gains, other income and interest not intended to cover costs, dividends and income from lending and repurchase transactions may be used for distribution.

• Lupus alpha Fonds – Lupus alpha Micro Champions

The objective of the investment policy is to achieve the highest possible growth in value. At least 51% of the value of the subfund is invested in micro, small and medium-sized European companies with a maximum market capitalisation of EUR 1 billion.

The sub-fund considers risks related to sustainability when making investment decisions. The fund manager examines the ESG risks arising for the sub-fund, taking into account the various requirements of the sub-fund's investment policy. In this process, securities or their issuers are analysed for sustainability risks using ESG criteria before any investment decision is made. ESG information and ESG criteria are taken into account for investment decisions, but are not decisive, so that the fund management may invest in securities and issuers that do not follow ESG criteria.

The investments underlying this sub-fund do not take into account the EU criteria for environmentally sustainable economic activities.

The management company has decided to issue different unit classes for the sub-fund. Investors therefore have a choice between unit classes "A", "C" and "CAV". The investment policy of the unit classes is identical to that of the sub-fund as a whole, the only differences being the charges incurred for these unit classes and the minimum investment amount.

Units in the sub-fund will be issued in distributing form only. Capital gains, other income and interest not intended to cover costs, dividends and income from lending and repurchase transactions may be used for distribution.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 1 – General (continued)

• Lupus alpha Fonds – Lupus alpha All Opportunities Fund

The objective of the investment policy is to achieve the highest possible growth in value. To this end, the sub-fund's assets are invested primarily in international small and mid-cap equities, fixed and floating rate securities including zero bonds, participatory notes and convertible bonds and bonds with warrants. The sub-fund's investments may at times have certain sector, country and industry-specific focuses in the interests of the investors.

In addition, the sub-fund may hold bank deposits and cash and cash equivalents.

Investments below speculative grade (e.g., B- according to Standard and Poor's and Fitch or B3 according to Moody's) are not authorised.

Units in other UCITS and/or other UCIs pursuant to article 7 (2) of the management regulations may be acquired for the sub-fund for up to 10% of its assets.

Long/short strategies may be entered into with the help of derivatives in order to exploit the relative overvaluation or undervaluation of individual stocks against each other or against indices. The aim is to generate additional income primarily through the use of equity, portfolio or index swaps as well as futures and forwards. Derivative positions built up by means of supplementary strategies do not have to be market neutral. Synthetic short positions built up as part of the swap strategies should not normally exceed 50 % of the fund's assets. The exposure from a swap in this context corresponds to the daily determined value of the net positions of the swap. Net amounts owed to the swap counterparty but not yet paid must be covered by liquid assets or securities.

The sub-fund considers risks related to sustainability when making investment decisions. The fund manager examines the sustainability risks arising for the fund, taking into account the various requirements of the sub-fund's investment policy. In this process, securities or their issuers are analysed for sustainability risks using ESG criteria before any investment decision is made. ESG information and ESG criteria are taken into account for investment decisions, but are not decisive, so that the fund management may invest in securities and issuers that do not follow ESG criteria.

The investments underlying this sub-fund do not take into account the EU criteria for environmentally sustainable economic activities.

The management company has decided to issue different unit classes for the sub-fund. Investors therefore have a choice between unit classes "A" and "C". The investment policy of the unit classes is identical to that of the sub-fund as a whole, the only differences being the charges incurred for these unit classes and the minimum investment amount.

Units in the sub-fund will be issued in distributing form only. Capital gains, other income and interest not intended to cover costs, dividends and income from lending and repurchase transactions may be used for distribution.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 1 – General (continued)

Lupus alpha Fonds – Lupus alpha Global Convertible Bonds

The objective of the investment policy is to achieve the highest possible growth in value. The sub-fund's assets may be invested entirely in securities, whereby at least 51% of the sub-fund's assets must be invested in convertible bonds.

To this end, the sub-fund's assets are invested in fixed and floating-rate securities, convertible bonds and bonds with warrants giving rights to securities, warrants, other fixed-income securities (including zero bonds), money market instruments and equities. Convertible bonds also include exchangeables, mandatory convertibles and warrant bonds (with options relating to securities).

In addition, the sub-fund may hold up to 49% of its assets in money market instruments, bank deposits and cash and cash equivalents.

Investments below speculative grade (e.g., B- according to Standard and Poor's and Fitch or B3 according to Moody's) are not authorised.

The derivatives, techniques and instruments listed under article 7 and 8 of the management regulations, such as futures, options and swaps, may be used for both hedging and investment purposes. However, the sub-fund's investment objectives as stated in the management regulations or the prospectus may not be changed, nor may the fundamental character of the sub-fund's investment policy.

The sub-fund considers risks related to sustainability when making investment decisions. The fund manager examines the ESG risks arising for the sub-fund, taking into account the various requirements of the sub-fund's investment policy. In this process, securities or their issuers are analysed for sustainability risks using ESG criteria before any investment decision is made. ESG information and ESG criteria are taken into account for investment decisions, but are not decisive, so that the fund management may invest in securities and issuers that do not follow ESG criteria.

The investments underlying this sub-fund do not take into account the EU criteria for environmentally sustainable economic activities.

C hedged and A hedged unit classes are currently issued under this sub-fund.

Units in the sub-fund are currently issued in distributing form only. Capital gains, other income and interest not intended to cover costs, dividends and income from lending and repurchase transactions may be used for distribution.

Units in other UCITS and/or other UCIs pursuant to article 7 (2) of the management regulations may be acquired for the sub-fund for up to 10% of its assets.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 2 – Summary of significant accounting policies

a) Calculation of net asset value

The fund currency ("fund currency") is the Euro.

The fund's financial statements are prepared in accordance with Luxembourg legal requirements, regulations governing collective investment undertakings and in accordance with the going concern principle.

The value of each unit ("net asset value" or also "unit value") shall be stated in the currency of the respective sub-fund and calculated under the supervision of the custodian by the management company or a third party appointed by it on the valuation date ("valuation date") of the respective sub-fund specified in the specific section of the prospectus at least twice each month. If a valuation date does not fall on a banking day in Luxembourg and/or Frankfurt am Main, the net asset value will be calculated on the next banking day in Luxembourg and Frankfurt am Main, Germany.

The net asset value is calculated by dividing the net assets of the respective sub-fund (fund assets less liabilities of the sub-fund) by the number of units of this sub-fund in circulation on the valuation date.

If different unit classes are issued within a sub-fund, the net asset value of each such unit class is calculated by dividing the net assets of this unit class by the number of units of this unit class in circulation on the valuation date.

The fund's total net assets ("net fund assets") consist of the sum of the net assets of the respective sub-funds and are expressed in euros ("the fund currency").

b) Valuation of securities holdings

The net assets of a sub-fund shall be calculated in accordance with the following principles:

- (a) The valuation of all transferable securities and money market instruments admitted to official listing or to another regulated market which operates regularly and is recognised and open to the public shall be made at the last available price and, if the security or money market instrument concerned is traded on several markets, on the basis of the last known price of the principal market for that security or money market instrument.
- (b) Securities and money market instruments that are neither officially listed on a stock exchange nor traded on another regulated market are valued, like all other legally permissible assets, at the respective market value as determined by the management company in good faith and in accordance with generally recognised valuation rules that may be verified by auditors. This also applies to the securities listed under (a) if their respective prices are not in line with the market.
- (c) Cash and cash equivalents are valued at their nominal value plus interest.
- (d) Fixed-term deposits may be valued at the yield rate provided that a corresponding agreement has been entered into between the management company and the counterparty, according to which the fixed-term deposits may be terminated at any time and the yield rate corresponds to the realisable value.
- (e) Investment units are valued at the last determined and available redemption price.
- (f) Financial futures contracts on securities, interest rates, indices, foreign exchange and other permissible financial instruments are valued at the last known prices on the relevant exchanges on the valuation date, provided they are listed on an exchange. If there is no stock exchange listing (primarily in the case of OTC transactions), the valuation is based on the probable realisable value, which is to be determined with caution and in good faith.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 2 – Summary of significant accounting policies (continued)

- (g) Options are generally valued at the last known prices of the relevant stock exchanges or broker prices on the valuation date. If a valuation date is also the settlement date of an option, the corresponding option shall be valued at its respective final settlement price ("settlement price").
- (h) Claims for repayment in respect of loans are valued on the basis of the market price of the assets transferred under the lending transaction in each case.
- (i) The pro rata interest accruing on securities is included insofar as it is not expressed in the market value.
- (j) All assets denominated in a currency other than the currency of the relevant sub-fund will be converted into the currency of that sub-fund at the latest available mid-market exchange rate.

c) Conversion of foreign currencies

The market value of securities and other investments denominated in a currency other than the currency of the relevant sub-fund will be converted into the currency of the sub-fund at the latest mid-market exchange rate.

d) Net realised gain/loss from sales of securities

Investment transactions are accounted for on the trade date (the date the order to buy or sell is executed). For trades into other collective investment schemes, transactions are accounted for on receipt of the trade confirmation from the underlying transfer agents.

Realised gains or losses on sales of investments are calculated on the average book cost. The associated foreign exchange movement between the date of purchase and date of sale of investments is included in realised gains or losses on investments. Unrealised gains or losses on holdings of investments are calculated on the total book cost and include the associated unrealised gains or losses on foreign exchange.

e) Income Recognition

Interest income is accrued daily and includes the amortisation of premiums and accretion of discounts, where applicable. Bank interest income is recognized on an accrual basis. Dividend income is accrued on the ex-dividend date. This income is shown net of any withholding taxes and adjusted accordingly when tax reclaims apply.

f) Valuation of forward exchange transactions

Unrealised gains or losses on outstanding forward currency exchange contracts are valued on the basis of currency exchange rates prevailing at the relevant valuation date. The changes in such amounts are included in the Statement of Operations and Changes in Net Assets under "Net change in unrealized appreciation/(depreciation) on forward currency exchange contracts". When a contract is closed, the realised gain/(loss) is recorded under "Net realized gain/(loss) on forward currency exchange contracts" in the Statement of Operations and Changes in Net Assets. Unrealised gains or losses are recorded under "Net unrealised appreciation/(depreciation) on forward currency exchange contracts" in the Statement of Net Assets.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 2 – Summary of significant accounting policies (continued)

g) Contract for differences

Contracts for difference are contracts entered into between a broker and the Fund under which the parties agree to make payments to each other so as to replicate the economic consequences of holding a long or short position in the underlying security. Contracts for difference also mirror any corporate actions that take place.

Upon entering into contracts for difference, the Fund may be required to pledge to the broker an amount of cash and/or other assets equal to a certain percentage of the contract amount ("initial margin"). Subsequently, payments known as "variation margin" are made or received by the Fund periodically depending on fluctuations in the value of the underlying security.

The market value of CFDs is determined by the last known traded price on the exchange on which the underlying securities or assets are traded or admitted for trading. For underlying securities traded on markets closing after the time of the valuation, last known prices as of this time or such other time may be used.

Contracts for differences are marked to market daily based upon quotations from the market makers and the change in value, if any, is recorded as an unrealised gain or loss in the "Statement of Operations and Changes in Net Assets". Any payment received or paid to initiate a contract is recorded as a liability or asset in the "Statement of Net Assets". When the contract is terminated early, the Fund records a realised gain or loss for any payments received or paid.

h) Reference Currency and Exchange Rates

The reference currency of the FCP as reflected in the combined statements is EUR. The principal exchange rates applied are the latest exchange rates known at the time of the NAV calculation:

| Currency | Rate |
|----------|------------------------|
| EUR = 1 | as at 31 December 2024 |
| AUD | 0.598250 |
| USD | 1.039950 |
| CHF | 0.939907 |
| GBP | 0.828877 |
| HKD | 8.075576 |
| JPY | 163.095358 |
| NOK | 11.787521 |
| PLN | 4.276534 |
| SEK | 11.470025 |
| SGD | 1.414904 |

Note 3 – Management and performance fees

- 1. The management company shall receive the following management fee for the management of the sub- fund **Lupus alpha** Sustainable Smaller Euro Champions:
 - (a) for units of unit class A, a maximum of 1.50% p.a. of the applicable net asset value.
 - (b) for units of unit class C, a maximum of 1.00% p.a. of the applicable net asset value.

The management fee is calculated on each valuation date, set aside in the investment fund and paid out at the end of each month.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 3 – Management and performance fees (continued)

The management company may pass on parts of its management remuneration to intermediary bodies. The amount of this remuneration is assessed as a rule depending on the brokered Fund volume.

In addition, if the sub-fund's net assets perform positively during a fiscal year ("the accounting period"), the fund manager will receive a performance fee ("the outperformance fee") of the amount by which such performance exceeds that of the benchmark index EURO STOXX® TMI Small EUR Net Return (an index of Stoxx Limited, Zürich).

If the net assets of the sub-fund perform negatively during the accounting period, the fund manager will not receive a performance fee. Any negative performance relative to the benchmark index will be carried forward to the following accounting period. Payment of the performance fee is only possible again after this negative carry-forward has been offset. This shall include any underperformance amount from the five preceding accounting periods.

- (a) For units of unit class A, the performance fee is 17.50% of the outperformance.
- (b) For units of unit class C, the performance fee is 12.50% of the outperformance.

In accordance with the result of a daily comparison, an arithmetically accrued performance fee shall be set aside in the fund per unit issued or a provision already booked shall be released accordingly. Released provisions shall accrue to the sub-fund. A performance fee may only be withdrawn if corresponding provisions have been formed.

In the event of outperformance of the benchmark, the performance fee may be withdrawn if the unit value at the end of the accounting period is below the unit value of the beginning of the accounting period ("negative unit value performance").

- 2. The management company shall receive the following management fee for the management of the sub- fund **Lupus alpha** Smaller German Champions:
 - (a) for units of unit class A, a maximum of 1.50% p.a. of the applicable net asset value.
 - (b) for units of unit class C, a maximum of 1.00% p.a. of the applicable net asset value.
 - (c) for units of unit class CT, a maximum of 1.00% p.a. of the applicable net asset value.
 - (d) for units of unit class CAV, a maximum of 1.75% p.a. of the applicable net asset value.

The management fee is calculated on each valuation date, set aside in the investment fund and paid out at the end of each month.

The management company may pass on parts of its management remuneration to intermediary bodies. The amount of this remuneration is assessed as a rule depending on the brokered Fund volume.

In addition, if the sub-fund's net assets perform positively during a fiscal year ("the accounting period"), the fund manager will receive a performance fee of the amount by which such performance exceeds that of the benchmark index ("the outperformance"). The benchmark index is composed of the MDAX® Performance Index and SDAX® Performance Index at a ratio of 50/50. Both indices are administered by STOXX Limited, Zürich, Switzerland.

If the net assets of the sub-fund perform negatively during the accounting period, the fund manager will not receive a performance fee. Any negative performance relative to the benchmark index will be carried forward to the following accounting period. Payment of the performance fee is only possible again after this negative carry-forward has been offset. This shall include any underperformance amount from the five preceding accounting periods.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 3 – Management and performance fees (continued)

- (a) For units of unit class A, the performance fee is 17.50% of the outperformance.
- (b) For units of unit class C, the performance fee is 12.50% of the outperformance.
- (c) For units of unit class CT, the performance fee is 12.50% of the outperformance.

In accordance with the result of a daily comparison, an arithmetically accrued performance fee shall be set aside in the fund per unit issued or a provision already booked shall be released accordingly. Released provisions shall accrue to the sub-fund. A performance fee may only be withdrawn if corresponding provisions have been formed.

In the event of outperformance of the benchmark, the performance fee may be withdrawn if the unit value at the end of the accounting period is below the unit value of the beginning of the accounting period ("negative unit value performance").

- 3. The management company shall receive the following management fee for the management of the sub-fund **Lupus alpha Micro Champions**:
 - (a) for units of unit class A, a maximum of 1.80% p.a. of the applicable net asset value.
 - (b) for units of unit class C, a maximum of 0.90% p.a. of the applicable net asset value.
 - (c) for units of unit class CAV, a maximum of 2.00% p.a. of the applicable net asset value.

The management fee is calculated on each valuation date, set aside in the investment fund and paid out at the end of each month.

The management company may pass on parts of its management remuneration to intermediary bodies. The amount of this remuneration is assessed as a rule depending on the brokered Fund volume.

In addition, the fund manager will receive a performance fee of the amount by which the sub-fund's net asset value outperforms the benchmark index MSCI Europe Micro Cap Net Total Return (EUR) (an index of MSCI Inc., New York) during a fiscal year ("the accounting period").

Any negative performance relative to the benchmark index will be carried forward to the following accounting period. Payment of the performance fee is only possible again after this negative carry-forward has been offset. This shall include any underperformance amount from the five preceding accounting periods.

- (a) For units of unit class A, the performance fee is 20.00% of the outperformance.
- (b) For units of unit class C, the performance fee is 20.00% of the outperformance.

In accordance with the result of a daily comparison, an arithmetically accrued performance fee shall be set aside in the fund per unit issued or a provision already booked shall be released accordingly. Released provisions shall accrue to the sub-fund. A performance fee may only be withdrawn if corresponding provisions have been formed.

In the event of outperformance of the benchmark, the performance fee may be withdrawn if the unit value at the end of the accounting period is below the unit value of the beginning of the accounting period ("negative unit value performance").

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 3 – Management and performance fees (continued)

- 4. The management company shall receive the following management fee for the management of the sub-fund **Lupus alpha All Opportunities Fund**:
 - (a) for units of unit class A, a maximum of 1.80% p.a. of the applicable net asset value.
 - (b) for units of unit class C, a maximum of 1.00% p.a. of the applicable net asset value.

The management fee is calculated on each valuation date, set aside in the investment fund and paid out at the end of each month.

The management company may pass on parts of its management remuneration to intermediary bodies. The amount of this remuneration is assessed as a rule depending on the brokered Fund volume.

In addition, the fund manager will receive a performance fee for class C and class A units equal to 20% of the amount by which the performance of the net assets of the sub-fund exceeds that of ESTR (ESTRON Index) + 200 basis points ("the benchmark") during a fiscal year "the accounting period"). Any negative performance relative to the benchmark will be carried forward to the following accounting period. Payment of the performance fee is only possible again after this negative carry-forward has been offset. This shall include any underperformance amount from the five preceding accounting periods.

In accordance with the result of a daily comparison, an arithmetically accrued performance fee shall be set aside in the fund per unit issued or a provision already booked shall be released accordingly. Released provisions shall accrue to the sub-fund. A performance fee may only be withdrawn if corresponding provisions have been formed.

In the event of outperformance of the benchmark, the performance fee may be withdrawn if the unit value at the end of the accounting period is below the unit value of the beginning of the accounting period ("negative unit value performance").

- 5. The management company shall receive the following management fee for the management of the sub-fund **Lupus alpha Global Convertible Bonds Fund**:
 - (a) for units of unit class A, a maximum of 1.20% p.a. of the applicable net asset value.
 - (b) for units of unit class C, a maximum of 0.60% p.a. of the applicable net asset value.

The management fee is calculated on each valuation date, set aside in the investment fund and paid out at the end of each month.

The management company may pass on parts of its management remuneration to intermediary bodies. The amount of this remuneration is assessed as a rule depending on the brokered Fund volume.

In addition, the fund manager will receive a performance fee of 10% of the amount by which the sub- fund's net asset value outperforms the benchmark index Refinitiv Global Focus Convertible Bonds Hedged (EUR) Index (an index of Refinitiv Inc., New York) during a fiscal year ("the accounting period"). Any negative performance relative to the benchmark index will be carried forward to the following accounting period. Payment of the performance fee is only possible again after this negative carry-forward has been offset. This shall include any underperformance amount from the five preceding accounting periods.

In accordance with the result of a daily comparison, an arithmetically accrued performance fee shall be set aside in the fund per unit issued or a provision already booked shall be released accordingly. Released provisions shall accrue to the sub-fund. A performance fee may only be withdrawn if corresponding provisions have been formed.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 3 – Management and performance fees (continued)

In the event of outperformance of the benchmark, the performance fee may be withdrawn if the unit value at the end of the accounting period is below the unit value of the beginning of the accounting period ("negative unit value performance").

There was no performance fee during the reporting period.

Note 4 – Subscription tax and Savings Directive

(a) Tax treatment of the fund

The fund's assets shall be subject in the Grand Duchy of Luxembourg to a quarterly taxe d'abonnement ("subscription tax") of 0.05 % p.a. of the net fund assets reported at the end of the quarter.

With the exception of a one-off tax of EUR 1,250, which was paid when the fund was established, income from the investment of the fund's assets is not subject to taxation in Luxembourg; it may, however, be subject to any withholding taxes in countries in which the fund's assets are invested. Neither the management company nor the custodian will obtain receipts for such withholding taxes individually or for all unitholders.

The above information is based on the current legal situation and administrative practice and is subject to change.

(b) Tax treatment of unitholders – Savings Directive

The law of 21 June 2005 (the "law") transposed Council Directive 2003/48/EC on taxation of savings income in the form of interest payments (the "Savings Directive") into Luxembourg law.

The Savings Directive aims to ensure that interest payments from debt claims ("savings income") in one member state of the European Union ("member state") to individuals ("beneficial owners") resident in another member state are effectively taxed. For example, under the Savings Directive, member states are obliged to provide the competent authorities in the beneficial owner's member state with certain minimum information on interest income as well as on the identity of the beneficial owner ("exchange of information"). The exceptions are Austria, Belgium and Luxembourg, which will levy withholding taxes on this interest income for a transitional period.

Other countries, including Switzerland, dependent or associated territories of EU member states, the principalities of Monaco, Liechtenstein and Andorra, as well as the Republic of San Marino, have also taken similar measures with the exchange of information or withholding tax.

In Luxembourg, the law provides for the levying of a withholding tax, which will be increased in three steps from initially 15 % (1 July 2005 to 30 June 2008) to 20%(1 July 2008 to 30 June 2011) and finally to 35% (as of 1 July 2011).

However, § 9 of the law stipulates that no withholding tax is withheld provided that the beneficial owner authorises the paying agent in writing to pass on information as part of the exchange of information.

Dividends paid out by the sub-fund fall within the scope of the Savings Directive if more than 15% of the assets of the relevant portfolio are invested in debt claims (for definition see the law). The Savings Directive applies to redemption proceeds received by a unitholder on redemption of units where more than 40% of the relevant sub-fund's assets are invested in debt claims.

If the applicant provides the management company with incomplete and insufficient information as required by law, the management company shall be entitled to reject any application for units.

Notes to the Annual Report (as of 31 December 2024) (continued)

Note 5 – Transaction costs

For the year ended 31 December 2024, transaction costs for the purchase and sale of securities and derivatives amounted to:

| | Sub-Fund | |
|--|----------|--------------------------------|
| Sub-Fund | Currency | Total transaction costs |
| Lupus alpha Sustainable Smaller Euro Champions | EUR | 128,990 |
| Lupus alpha Smaller German Champions | EUR | 982,710 |
| Lupus alpha Micro Champions | EUR | 161,302 |
| Lupus alpha All Opportunities Fund | EUR | 108,689 |
| Lupus alpha Global Convertible Bonds | EUR | 898 |

Note 6 – Significant events during the period

The Management Company terminated the Custodian, Central Administration, Registrar and Transfer Agent Agreement with CACEIS Investor Services Bank SA as of 18 January 2024. J.P. Morgan SE - Luxembourg Branch took over these duties as of 19 January 2024.

Note 7 – Subsequent events

There were no other significant changes after the financial year end date and no other significant events.

Note 8 – Obligations arising from forward transactions and disclosures in accordance with ESMA 2012/832

No efficient portfolio management techniques were used during the period.

As of 31 December 2024, the amount of collateral with the counterparty UBS London was 100,000.00 EUR.

Additional information about OTC derivatives (underlyings and unrealised income are shown in the respective portfolio):

| Sub-fund name | Counterparties | Type | |
|------------------------------------|----------------|------|--|
| Lupus alpha All Opportunities Fund | UBS London | Cash | |

Note 9 – Classification according to the SFDR (EU 2019/2088)

The information on the environmental and social characteristics of Lupus alpha Sustainable Smaller Euro Champions required under article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR) can be found in "Other Notes (unaudited)" and in article 50(2) of SFDR-RTS.

Note 10 – Disclosures pursuant to Regulation (EU) 2015/2365 on transparency of securities financing transactions (SFTR) and of reuse and amending Regulation (EU) No 648/2012 - Disclosure according to article A.

In the reporting period, there were no securities financing transactions pursuant to the above-mentioned legal provision.

Lupus alpha Sustainable Smaller Euro Champions Schedule of investments and other net assets As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|---|---------------------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted | to an official exchange listing | ; | | |
| Equities | | | | |
| Austria | | | | |
| ANDRITZ AG | EUR | 19,000 | 930,620 | 1.70 |
| DO & CO AG | EUR | 6,600 | 1,188,000 | 2.16 |
| UNIQA Insurance Group AG | EUR | 54,000 | 422,820 | 0.77 |
| Vienna Insurance Group AG | EUR | 26,000 | 789,100 | 1.44 |
| Wienerberger AG | EUR | 44,000_ | 1,178,320 4,508,860 | 2.15 8.22 |
| | | | 4,500,000 | 0.22 |
| Belgium | EIID | 45,000 | 925 200 | 1.52 |
| Azelis Group NV D'ieteren Group | EUR EUR | 45,000 6,200 | 835,200 988,280 | 1.52 1.80 |
| Fagron | EUR | 49,000 | 988,280 820,260 | 1.50 |
| Kinepolis Group NV | EUR | 27,000 | 1,048,950 | 1.91 |
| Kinepolis Group IVV | Lok | 27,000_ | 3,692,690 | 6.73 |
| | | _ | | |
| Finland | DID | 40.000 | 1.267.200 | 2.40 |
| Huhtamaki OYJ | EUR | 40,000 | 1,367,200 | 2.49 |
| Metso OYJ Stora Enso OYJ 'R' | EUR EUR | 116,000 52,000 | 1,041,680 505,336 | 1.90 0.92 |
| Valmet OYJ | EUR | 48,000 | 1,119,840 | 2.04 |
| valuet 013 | LUK | 48,000_ | 4,034,056 | 7.35 |
| | | | .,00 .,000 | |
| France | | | = | |
| Alten SA | EUR | 8,400 | 649,740 | 1.19 |
| Elis SA | EUR | 30,000 | 561,900 | 1.02 |
| Forvia SE IPSOS SA | EUR EUR | 57,000 29,000 | 492,480 1,328,780 | 0.90 2.42 |
| Nexans SA | EUR | 5,200 | 536,120 | 0.98 |
| Quadient SA | EUR | 33,000 | 611,160 | 1.11 |
| SCOR SE | EUR | 43,000 | 1,010,500 | 1.84 |
| SEB SA | EUR | 11,000 | 950,400 | 1.73 |
| Societe BIC SA | EUR | 15,500 | 974,950 | 1.78 |
| SOITEC | EUR | 12,500 | 1,060,625 | 1.93 |
| Sopra Steria Group | EUR | 5,700 | 950,190 | 1.73 |
| SPIE SA | EUR | 50,700 | 1,499,706 | 2.73 |
| Technip Energies NV | EUR | 51,600 | 1,320,960 | 2.41 |
| Teleperformance SE | EUR | 18,400 | 1,503,648 | 2.74 |
| Virbac SACA | EUR | 3,100 | 974,950 | 1.78 |
| | | _ | 14,426,109 | 26.29 |
| Germany | | | | |
| Bechtle AG | EUR | 14,000 | 435,400 | 0.79 |
| | 42 | | | |

Lupus alpha Sustainable Smaller Euro Champions Schedule of investments and other net assets (continued) As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|---|---------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an offic | ial exchange listin | g (continued) | | |
| Equities (continued) | | | | |
| Germany (continued) FUCHS SE Preference | EUR | 32,000 | 1,333,120 | 2.43 |
| GEA Group AG | EUR | 34,000 | 1,625,880 | 2.96 |
| Gerresheimer AG | EUR | 20,500 | 1,455,500 | 2.65 |
| IONOS Group SE | EUR | 33,000 | 721,050 | 1.31 |
| Jenoptik AG | EUR | 21,000 | 471,240 | 0.86 |
| KION Group AG | EUR | 25,300 | 806,058 | 1.47 |
| Krones AG | EUR | 6,408 | 768,960 | 1.40 |
| Puma SE | EUR | 22,000 | 975,920 | 1.78 |
| Schott Pharma AG & Co. KGaA | EUR | 19,000 | 478,040 | 0.87 |
| Siltronic AG | EUR | 10,000 | 465,000 | 0.85 |
| Sixt SE | EUR | 10,000 | 786,000 | 1.43 |
| Verbio SE | EUR | 22,000 | 260,260 | 0.48 |
| | | _ | 10,582,428 | 19.28 |
| Ireland | | | | |
| Glanbia plc | EUR | 111,000_ | 1,481,850 | 2.70 |
| | | | 1,481,850 | 2.70 |
| Italy | | | | |
| Danieli & C Officine Meccaniche SpA | EUR | 51,000 | 977,160 | 1.78 |
| FinecoBank Banca Fineco SpA | EUR | 48,000 | 805,920 | 1.47 |
| Intercos SpA | EUR | 24,000 | 334,080 | 0.61 |
| Maire SpA | EUR | 139,000 | 1,148,140 | 2.09 |
| OVS SpA, Reg. S, 144A | EUR | 36,000 | 122,328 | 0.23 |
| Reply SpA | EUR | 4,300 | 659,620 | 1.20 |
| Tinexta SpA | EUR | 34,000 | 269,280 | 0.49 |
| | | _ | 4,316,528 | 7.87 |
| Luxembourg | | | | |
| APERAM SA | EUR | 37,000_ | 927,220 | 1.69 |
| | | _ | 927,220 | 1.69 |
| Netherlands | | | | |
| Arcadis NV | EUR | 18,000 | 1,051,200 | 1.91 |
| ASR Nederland NV | EUR | 16,000 | 722,880 | 1.32 |
| Basic-Fit NV, Reg. S, 144A | EUR | 30,000 | 665,400 | 1.21 |
| Fugro NV | EUR | 85,000 | 1,393,150 | 2.54 |
| IMCD NV | EUR | 8,700 | 1,219,305 | 2.22 |
| Redcare Pharmacy NV, Reg. S, 144A | EUR | 6,200 | 816,540 | 1.49 |

Lupus alpha Sustainable Smaller Euro Champions Schedule of investments and other net assets (continued) As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|---|----------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an offic | ial exchange listing | g (continued) | | |
| Equities (continued) | | | | |
| Netherlands (continued) | | | | |
| TKH Group NV, CVA | EUR | 11,000 | 361,460 | 0.66 |
| | | _ | 6,229,935 | 11.35 |
| Spain | | | | |
| Acerinox SA | EUR | 64,000 | 599,680 | 1.09 |
| Construcciones y Auxiliar de Ferrocarriles SA | EUR | 12,000 | 415,800 | 0.76 |
| Global Dominion Access SA, Reg. S, 144A | EUR | 117,000 | 325,845 | 0.59 |
| | | | 1,341,325 | 2.44 |
| United Kingdom | | | | |
| Just Eat Takeaway.com NV, Reg. S, 144A | EUR | 88,000 | 1,167,320 | 2.13 |
| | | _ | 1,167,320 | 2.13 |
| United States of America | | | | |
| QIAGEN NV | EUR | 20,500 | 882,423 | 1.61 |
| | | _ | 882,423 | 1.61 |
| Total Equities | | _ | 53,590,744 | 97.66 |
| 1 | | | | |
| Total Transferable securities and money market instruments admitted to an | n official exchange | listing | 53,590,744 | 97.66 |
| Total Investments | | _ | 53,590,744 | 97.66 |
| Cash | | | 1,191,328 | 2.17 |
| Other assets/(liabilities) | | _ | 94,842 | 0.17 |
| Total net assets | | = | 54,876,914 | 100.00 |

The accompanying notes are an integral part of the Financial Statements

Lupus alpha Smaller German Champions Schedule of investments and other net assets As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an official | exchange listing | | | |
| Equities | | | | |
| Germany | | | | |
| 2G Energy AG | EUR | 125,000 | 2,875,000 | 0.63 |
| AlzChem Group AG | EUR | 108,200 | 6,167,400 | 1.35 |
| Atoss Software SE | EUR | 64,000 | 7,308,800 | 1.60 |
| Aurubis AG | EUR | 71,000 | 5,445,700 | 1.19 |
| Auto1 Group SE, Reg. S, 144A | EUR | 550,000 | 8,580,000 | 1.88 |
| Bechtle AG | EUR | 120,000 | 3,732,000 | 0.82 |
| Bilfinger SE | EUR | 205,000 | 9,481,250 | 2.07 |
| CECONOMY AG | EUR | 900,000 | 2,370,600 | 0.52 |
| Cewe Stiftung & Co. KGaA | EUR | 67,000 | 6,927,800 | 1.52 |
| Commerzbank AG | EUR | 300,000 | 4,717,500 | 1.03 |
| CTS Eventim AG & Co. KGaA | EUR | 89,000 | 7,266,850 | 1.59 |
| Delivery Hero SE, Reg. S, 144A | EUR | 275,000 | 7,458,000 | 1.63 |
| Dermapharm Holding SE | EUR | 168,000 | 6,535,200 | 1.43 |
| Deutsche Lufthansa AG | EUR | 1,070,000 | 6,608,320 | 1.45 |
| Deutz AG | EUR | 2,050,000 | 8,277,900 | 1.81 |
| Eckert & Ziegler SE | EUR | 173,000 | 7,698,500 | 1.68 |
| Elmos Semiconductor SE | EUR | 100,000 | 6,800,000 | 1.49 |
| Energiekontor AG | EUR | 53,000 | 2,604,950 | 0.57 |
| Evotec SE | EUR | 550,000 | 4,507,250 | 0.99 |
| flatexDEGIRO AG | EUR | 570,000 | 8,421,750 | 1.84 |
| Formycon AG | EUR | 50,000 | 2,655,000 | 0.58 |
| Fresenius Medical Care AG | EUR | 347,000 | 15,323,520 | 3.35 |
| Fresenius SE & Co. KGaA | EUR | 133,000 | 4,460,820 | 0.98 |
| FUCHS SE Preference | EUR | 331,000 | 13,789,460 | 3.02 |
| GEA Group AG | EUR | 241,000 | 11,524,620 | 2.52 |
| Gerresheimer AG | EUR | 131,900 | 9,364,900 | 2.05 |
| GFT Technologies SE | EUR | 256,000 | 5,657,600 | 1.24 |
| Heidelberg Materials AG | EUR | 50,000 | 5,965,000 | 1.31 |
| HelloFresh SE | EUR | 480,000 | 5,644,800 | 1.23 |
| Hensoldt AG | EUR | 130,000 | 4,485,000 | 0.98 |
| HUGO BOSS AG | EUR | 140,000 | 6,269,200 | 1.37 |
| Hypoport SE | EUR | 13,000 | 2,185,300 | 0.48 |
| Infineon Technologies AG | EUR | 110,000 | 3,454,000 | 0.76 |
| Instone Real Estate Group SE, Reg. S, 144A | EUR | 490,000 | 4,145,400 | 0.91 |
| IONOS Group SE | EUR | 480,000 | 10,488,000 | 2.29 |
| JDC Group AG | EUR | 108,000 | 2,462,400 | 0.54 |
| Jenoptik AG | EUR | 495,000 | 11,107,800 | 2.43 |
| JOST Werke SE, Reg. S, 144A | EUR | 255,000 | 11,602,500 | 2.54 |
| Jungheinrich AG Preference | EUR | 175,000 | 4,490,500 | 0.98 |
| K+S AG | EUR | 225,000 | 2,353,500 | 0.51 |
| KION Group AG | EUR | 154,000 | 4,906,440 | 1.07 |

Lupus alpha Smaller German Champions Schedule of investments and other net assets (continued) As at 31 December 2024

| Investments Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|---|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an official exchange listing | ng (continued) | | |
| Equities (continued) | | | |
| Germany (continued) | 4 40 000 | | • 40 |
| Knorr-Bremse AG EUR | 169,000 | 11,889,150 | 2.60 |
| Krones AG EUR | 92,000 | 11,040,000 | 2.42 |
| KWS Saat SE & Co. KGaA EUR | 49,000 | 2,881,200 | 0.63 |
| LANXESS AG EUR | 259,000 | 6,107,220 | 1.34 |
| LEG Immobilien SE EUR | 116,000 | 9,488,800 | 2.08 |
| LPKF Laser & Electronics SE EUR | 270,000 | 2,411,100 | 0.53 |
| Mensch und Maschine Software SE EUR | 85,000 | 4,496,500 | 0.98 |
| Nagarro SE EUR | 41,000 | 3,245,150 | 0.71 |
| Nemetschek SE EUR | 78,000 | 7,300,800 | 1.60 |
| Norma Group SE EUR PATRIZIA SE EUR | 166,000 | 2,480,040 | 0.54 |
| PATRIZIA SE EUR ProSiebenSat.1 Media SE EUR | 330,000 170,000 | 2,607,000 842,520 | 0.57 0.18 |
| Puma SE EUR | 328,000 | 14,550,080 | 3.18 |
| Rational AG EUR | 10,200 | 8,404,800 | 1.84 |
| RENK Group AG EUR | 315,000 | 5,775,210 | 1.84 |
| Scout24 SE, Reg. S, 144A EUR | 124,000 | 10,552,400 | 2.31 |
| SCULL24 SE, Reg. 3, 144A SGL Carbon SE EUR | 383,000 | 1,532,000 | 0.34 |
| Siemens Energy AG EUR | 60,000 | 3,022,800 | 0.66 |
| Siltronic AG EUR | 65,000 | 3,022,500 | 0.66 |
| Sixt SE EUR | 116,000 | 9,117,600 | 1.99 |
| Stroeer SE & Co. KGaA EUR | 46,000 | 2,118,760 | 0.46 |
| SUSS MicroTec SE EUR | 128,000 | 6,227,200 | 1.36 |
| Symrise AG 'A' EUR | 30,000 | 3,079,500 | 0.67 |
| Talanx AG EUR | 105,000 | 8,625,750 | 1.89 |
| Traton SE EUR | 58,000 | 1,621,100 | 0.35 |
| Verbio SE EUR | 130,000 | 1,537,900 | 0.34 |
| Vossloh AG EUR | 150,000 | 6,457,500 | 1.41 |
| Wacker Chemie AG EUR | 35,000 | 2,451,400 | 0.54 |
| Zalando SE, Reg. S, 144A EUR | 215,000 | 6,963,850 | 1.52 |
| | | 425,970,360 | 93.19 |
| Netherlands | _ | | <u> </u> |
| Redcare Pharmacy NV, Reg. S, 144A EUR | 122,000 | 16,067,400 | 3.51 |
| Todalia Findinacy 111, 10g. 5, 11111 | 122,000_ | | |
| | _ | 16,067,400 | 3.51 |
| Total Equities | - | 442,037,760 | 96.70 |
| Total Transferable securities and money market instruments admitted to an official exchange | e listing | 442,037,760 | 96.70 |

Lupus alpha Smaller German Champions Schedule of investments and other net assets (continued) As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|----------------------------|----------|----------------------------|------------------------|--------------------|
| Total Investments | | - | 442,037,760 | 96.70 |
| Cash | | _ | 12,498,019 | 2.73 |
| Other assets/(liabilities) | | - | 2,580,122 | 0.57 |
| Total net assets | | - | 457,115,901 | 100.00 |

Lupus alpha Micro Champions Schedule of investments and other net assets As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|---|--------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an officia | l exchange listing | | | |
| Equities | | | | |
| Austria | | | | |
| DO & CO AG | EUR | 12,000_ | 2,160,000 | 1.85 |
| | | _ | 2,160,000 | 1.85 |
| Finland | | | | |
| Admicom OYJ | EUR | 19,000 | 901,550 | 0.77 |
| Harvia OYJ, Reg. S | EUR | 43,000 | 1,842,550 | 1.58 |
| | | _ | 2,744,100 | 2.35 |
| France | | | | |
| Bilendi SA | EUR | 94,000 | 1,673,200 | 1.43 |
| Planisware SA | EUR | 92,000 | 2,531,380 | 2.17 |
| Sword Group | EUR | 38,000 | 1,358,500 | 1.17 |
| TFF Group | EUR | 43,000 | 1,221,200 | 1.05 |
| | | _ | 6,784,280 | 5.82 |
| Germany | | | | |
| Amadeus Fire AG | EUR | 27,000 | 2,054,700 | 1.76 |
| Basler AG | EUR | 147,000 | 899,640 | 0.77 |
| Brockhaus Technologies AG, Reg. S, 144A | EUR | 86,600 | 2,017,780 | 1.73 |
| Clearvise AG | EUR | 824,334 | 1,368,394 | 1.17 |
| DEFAMA AG | EUR | 73,000 | 2,044,000 | 1.75 |
| Deutz AG | EUR | 349,000 | 1,409,262 | 1.21 |
| Eckert & Ziegler SE | EUR | 50,000 | 2,225,000 | 1.91 |
| Einhell Germany AG | EUR | 36,100 | 2,274,300 | 1.95 |
| Energiekontor AG | EUR | 21,500 | 1,056,725 | 0.91 |
| JOST Werke SE, Reg. S, 144A | EUR | 60,000 | 2,730,000 | 2.34 |
| Limes Schlosskliniken AG | EUR | 6,100 | 2,019,100 | 1.73 |
| Mensch und Maschine Software SE | EUR | 73,000 | 3,861,700 | 3.31 |
| Netfonds AG Nexus AG | EUR EUR | 39,000 | 1,692,600 2,780,000 | 1.45 2.38 |
| Norma Group SE | EUR | 40,000 88,000 | 1,314,720 | 1.13 |
| Nynomic AG | EUR | 82,000 | 1,443,200 | 1.13 |
| SAF-Holland SE | EUR | 111,000 | 1,640,580 | 1.41 |
| Vossloh AG | EUR | 38,000 | 1,635,900 | 1.40 |
| Zeal Network SE | EUR | 40,916 | 2,045,800 | 1.76 |
| | - | | 36,513,401 | 31.31 |
| Ireland | | | | |
| Irish Continental Group plc | EUR | 434,000 | 2,256,800 | 1.93 |
| | | _ | 2,256,800 | 1.93 |
| The accompanying notes are an integral part of the Financial Statements | | | | |

Lupus alpha Micro Champions Schedule of investments and other net assets (continued) As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|---------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an office | ial exchange listin | g (continued) | | |
| Equities (continued) | | | | |
| Italy | | | | |
| Cembre SpA | EUR | 50,000 | 2,082,500 | 1.79 |
| Dexelance SpA | EUR | 153,000 | 1,386,180 | 1.19 |
| Fine Foods & Pharmaceuticals NTM | EUR | 145,800 | 1,093,500 | 0.94 |
| LU-VE SpA | EUR | 66,000 | 1,831,500 | 1.57 |
| Moltiply Group SpA | EUR | 60,800 | 2,210,080 956,800 | 1.89 |
| Next Geosolutions Europe SpA | EUR EUR | 115,000 57,000 | 3,100,800 | 0.82 |
| Pharmanutra SpA Planetel SpA | EUR | 8,000 | 37,280 | 2.66 0.03 |
| Racing Force SpA | EUR | 427,562 | 1,646,114 | 1.41 |
| Racing Porce SpA | LOK | 427,302 | | |
| | | _ | 14,344,754 | 12.30 |
| Norway | | | | |
| Kitron ASA | NOK | 248,000 | 710,160 | 0.61 |
| Norconsult Norge A/S | NOK | 495,000_ | 1,854,597 | 1.59 |
| | | _ | 2,564,757 | 2.20 |
| Poland | | | | |
| Grupa Pracuj SA | PLN | 95,000 | 1,270,818 | 1.09 |
| • | | | 1,270,818 | 1.09 |
| Sweden | | | | |
| Alimak Group AB, Reg. S, 144A | SEK | 130,000 | 1,331,356 | 1.14 |
| Anniak Gloup AB, Reg. 3, 144A Apotea Sverige AB | SEK | 150,000 | 1,099,795 | 0.94 |
| BioGaia AB 'B' | SEK | 133,000 | 1,298,269 | 1.11 |
| BoneSupport Holding AB, Reg. S, 144A | SEK | 42,000 | 1,417,159 | 1.22 |
| BTS Group AB 'B' | SEK | 84,000 | 1,927,161 | 1.65 |
| CTT Systems AB | SEK | 55,000 | 1,348,192 | 1.16 |
| Hanza AB | SEK | 367,000 | 2,455,525 | 2.11 |
| Hexatronic Group AB | SEK | 195,000 | 615,440 | 0.53 |
| NCAB Group AB | SEK | 245,000 | 1,378,506 | 1.18 |
| Rejlers AB 'B' | SEK | 188,000 | 2,325,503 | 1.99 |
| | | _ | 15,196,906 | 13.03 |
| | | _ | | |
| Switzerland | CHE | £ 100 | 1 246 600 | 1 16 |
| Comet Holding AG | CHF | 5,100 | 1,346,600 | 1.16 |
| Kuros Biosciences AG | CHF | 22,000 | 499,071 | 0.43 |
| TX Group AG | CHF | 6,600_ | 1,274,911 | 1.09 |
| | | _ | 3,120,582 | 2.68 |

Lupus alpha Micro Champions Schedule of investments and other net assets (continued) As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|-----------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an official | exchange listing (| continued) | | |
| Equities (continued) | | | | |
| United Kingdom | | | | |
| Advanced Medical Solutions Group plc | GBP | 533,000 | 1,265,464 | 1.08 |
| Ashtead Technology Holdings plc | GBP | 207,000 | 1,359,638 | 1.17 |
| Baltic Classifieds Group plc | GBP | 948,000 | 3,610,371 | 3.10 |
| Bloomsbury Publishing plc | GBP | 275,000 | 2,213,939 | 1.90 |
| Coats Group plc | GBP | 2,520,000 | 2,830,563 | 2.43 |
| Essentra plc | GBP | 980,000 | 1,537,777 | 1.32 |
| Focusrite plc | GBP | 240,000 | 744,809 | 0.64 |
| Hollywood Bowl Group plc | GBP | 900,000 | 3,199,786 | 2.74 |
| Kitwave Group plc | GBP | 500,000 | 1,904,204 | 1.63 |
| Moonpig Group plc | GBP | 410,000 | 1,030,259 | 0.88 |
| Mortgage Advice Bureau Holdings Ltd. | GBP | 170,000 | 1,315,347 | 1.13 |
| Porvair plc | GBP | 218,000 | 1,844,378 | 1.58 |
| Zoo Digital Group plc | GBP | 1,078,000 | 487,199 | 0.42 |
| | | _ | 23,343,734 | 20.02 |
| United States of America | | | | |
| Public Policy Holding Co., Inc., Reg. S | GBP | 950,000 | 1,568,558 | 1.35 |
| Somero Enterprises, Inc., Reg. S | GBP | 347,000 | 1,380,066 | 1.18 |
| | | _ | 2,948,624 | 2.53 |
| Total Equities | | <u> </u> | 113,248,756 | 97.11 |
| Total Transferable securities and money market instruments admitted to an o | official exchange lis | sting _ | 113,248,756 | 97.11 |
| Total Investments | | _ | 113,248,756 | 97.11 |
| Cash | | _ | 3,110,975 | 2.67 |
| Other assets/(liabilities) | | - | 262,626 | 0.22 |
| Total net assets | | _ | 116,622,357 | 100.00 |
| | | = | , , , , , , , , , | |

Lupus alpha All Opportunities Fund Schedule of investments and other net assets As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|---|--------------------------|--------------------------------------|--|------------------------------|
| Transferable securities and money market instruments admitted to an officia | l exchange listin | g | | |
| Bonds | | | | |
| Sweden Lansforsakringar Hypotek AB, Reg. S 0.625% 27/03/2025 | EUR | 2,000,000_ | 1,989,325 1,989,325 | 3.12 |
| Total Bonds | | _ _ _ | 1,989,325 | 3.12 |
| Convertible Bonds | | | | |
| Austria voestalpine AG, Reg. S 2.75% 28/04/2028 | EUR | 3,000,000_ | 2,875,470 2,875,470 | 4.52 |
| Belgium Sagerpar SA, Reg. S 0% 01/04/2026 | EUR | 1,500,000_ | 1,443,750 1,443,750 | 2.27 |
| France Selena SARL, Reg. S 0% 25/06/2025 | EUR | 1,500,000 | 1,487,250 1,487,250 | 2.33 |
| Germany Bechtle AG, Reg. S 2% 08/12/2030 Deutsche Lufthansa AG, Reg. S 2% 17/11/2025 RAG-Stiftung, Reg. S 0% 17/06/2026 | EUR EUR EUR | 1,000,000 1,500,000 1,500,000 | 952,898 1,497,463 1,451,182 3,901,543 | 1.50 2.35 2.28 6.13 |
| <i>Italy</i> Davide Campari-Milano NV, Reg. S 2.375% 17/01/2029 DiaSorin SpA, Reg. S 0% 05/05/2028 | EUR EUR | 2,000,000 2,000,000 | 1,913,108 1,764,533 3,677,641 | 3.00 2.77 5.77 |
| Total Convertible Bonds | | | 13,385,654 | 21.02 |
| Equities | | | | |
| Austria CA Immobilien Anlagen AG EVN AG Flughafen Wien AG Frauenthal Holding AG The accompanying notes are an integral part of the Financial Statements | EUR EUR EUR EUR | 45,000 50,000 11,000 74,977 | 1,049,400 1,100,000 585,200 1,641,996 | 1.65 1.73 0.92 2.58 |

Lupus alpha All Opportunities Fund Schedule of investments and other net assets (continued) As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|---|---|--|--|
| Transferable securities and money market instruments admitted to an office | cial exchange listir | ng (continued) | | |
| Equities (continued) | | | | |
| Austria (continued) Frequentis AG OMV AG Strabag SE 'BR' UNIQA Insurance Group AG | EUR EUR EUR EUR | 45,000 14,000 23,300 240,000 | 1,247,400 522,760 920,350 1,879,200 8,946,306 | 1.96 0.82 1.44 2.95 14.05 |
| Belgium D'ieteren Group Kinepolis Group NV | EUR EUR | 2,500 14,000 | 398,500 543,900 942,400 | 0.63 0.85 1.48 |
| France Verallia SA, Reg. S, 144A | EUR | 25,000 | 590,500 590,500 | 0.93 |
| Germany 2G Energy AG ADM Hamburg AG Deutsche Wohnen SE Deutz AG Dierig Holding AG Duerr AG FRIWO AG H&R GmbH & Co. KGaA LEG Immobilien SE OTI Greentech AG Puma SE SPORTTOTAL AG Tonies SE 'A' Vossloh AG Greece JUMBO SA Metlen Energy & Metals SA | EUR | 7,700 505 50,000 260,000 43,500 25,000 33,450 64,700 12,500 9,318 12,000 674,000 90,000 35,000 50,000 10,000 | 177,100 118,675 1,152,500 1,049,880 384,975 536,000 762,660 219,333 1,022,500 447 532,320 168,500 682,200 1,506,750 8,313,840 1,267,000 331,400 1,598,400 | 0.28 0.19 1.81 1.65 0.60 0.84 1.20 0.34 1.61 - 0.84 0.26 1.07 2.37 13.06 |
| Ireland Falcon Oil & Gas Ltd. | GBP | 5,878,000 | 315,243 | 0.49 |

Lupus alpha All Opportunities Fund Schedule of investments and other net assets (continued) As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|--------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an official | al exchange listin | g (continued) | | |
| Equities (continued) | | | | |
| Ireland (continued) | | | | |
| Uniphar plc | EUR | 305,000_ | 646,600 | 1.02 |
| | | _ | 961,843 | 1.51 |
| Italy | | | | |
| Banca Monte dei Paschi di Siena SpA | EUR | 35,000 | 238,210 | 0.37 |
| Buzzi SpA | EUR | 22,000 | 782,760 | 1.23 |
| Davide Campari-Milano NV | EUR | 50,000 | 300,900 | 0.47 |
| Fila SpA | EUR | 100,000 | 1,038,000 | 1.63 |
| FinecoBank Banca Fineco SpA | EUR | 50,000 | 839,500 | 1.32 |
| Immobiliare Grande Distribuzione SIIQ SpA, REIT | EUR | 195,000 | 487,500 | 0.77 |
| Maire SpA | EUR | 80,000 | 660,800 | 1.04 |
| Seco SpA | EUR | 550,000 | 994,400 | 1.56 |
| | | | 5,342,070 | 8.39 |
| N. d I I. | | | | |
| Netherlands CM com NV, Dog. S | EUR | 49,500 | 279,180 | 0.44 |
| CM.com NV, Reg. S Corbion NV | EUR | 25,000 | 537,500 | 0.44 |
| Coloioli NV Ctac NV | EUR | 248,000 | 739,040 | 1.16 |
| Fugro NV | EUR | 30,000 | 491,700 | 0.77 |
| Koninklijke Heijmans N.V, CVA | EUR | 20,000 | 609,000 | 0.77 |
| Koninklijke Vopak NV | EUR | 15,000 | 642,000 | 1.01 |
| SBM Offshore NV | EUR | 20,000 | 336,200 | 0.53 |
| SDM Offshole IVV | LUK | 20,000_ | 3,634,620 | 5.71 |
| | | _ | 3,034,020 | 3.71 |
| Poland Develia SA | PLN | 250,000 | 222 149 | 0.50 |
| Devena SA | PLN | 230,000 | 322,148 | 0.50 |
| | | - | 322,148 | 0.50 |
| Spain | | | | |
| Acerinox SA | EUR | 105,000 | 983,850 | 1.54 |
| Construcciones y Auxiliar de Ferrocarriles SA | EUR | 14,000 | 485,100 | 0.76 |
| Facephi Biometria SA | EUR | 100,000 | 162,500 | 0.26 |
| Prosegur Cash SA, Reg. S, 144A | EUR | 2,275,000 | 1,228,500 | 1.93 |
| Tubacex SA | EUR | 642,000 | 2,115,390 | 3.32 |
| | | | 4,975,340 | 7.81 |
| Switzerland | | | | |
| Switzeriana Clariant AG | CHF | 50,000 | 536,048 | 0.84 |
| Highlight Communications AG 'BR' | EUR | 664,000 | 756,960 | 1.19 |
| Inginight Communications AC DK | EUK | 004,000 | 130,700 | 1.17 |

Lupus alpha All Opportunities Fund Schedule of investments and other net assets (continued) As at 31 December 2024

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|---------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an official | al exchange listing | g (continued) | | |
| Equities (continued) | | | | |
| Switzerland (continued) | | | | |
| Naturenergie Holding AG | CHF | 20,300 | 748,458 | 1.17 |
| | | _ | 2,041,466 | 3.20 |
| United Kingdom | | | | |
| Aston Martin Lagonda Global Holdings plc, Reg. S, 144A | GBP | 150,000 | 188,552 | 0.30 |
| Crest Nicholson Holdings plc | GBP | 300,000 | 600,548 | 0.94 |
| Just Eat Takeaway.com NV, Reg. S, 144A | EUR | 44,000 | 583,660 | 0.92 |
| Williams Grand Prix Holdings plc | EUR | 60,000_ | 600 | _ |
| | | _ | 1,373,360 | 2.16 |
| United States of America | | | | |
| ADTRAN Holdings, Inc. | EUR | 58,000 | 452,864 | 0.71 |
| Titan Cement International SA | EUR | 25,000 | 996,250 | 1.57 |
| ULURU, Inc. | USD | 50,000 | 482 | |
| | | _ | 1,449,596 | 2.28 |
| Total Equities | | _ _ | 40,491,889 | 63.59 |
| Total Transferable securities and money market instruments admitted to an | official exchange | listing | 55,866,868 | 87.73 |
| Total Investments | | _ | 55,866,868 | 87.73 |
| Cash | | _ | 7,407,146 | 11.63 |
| Other assets/(liabilities) | | _ | 404,155 | 0.64 |
| Total net assets | | | 63,678,169 | 100.00 |

Lupus alpha All Opportunities Fund Schedule of investments and other net assets As at 31 December 2024

Financial Futures Contracts

| | | | Global | Unrealised | |
|---|-----------|----------|-------------|-------------|----------|
| | Number of | | Exposure | Gain/(Loss) | % of Net |
| Security Description | Contracts | Currency | EUR | EUR | Assets |
| EURO STOXX 50 Index, 21/03/2025 | (125) | EUR | (6,101,250) | 119,375 | 0.19 |
| STOXX Europe 600 Index, 21/03/2025 | (325) | EUR | (8,214,375) | 194,550 | 0.30 |
| Total Unrealised Gain on Financial Futures Contracts | | | _ | 313,925 | 0.49 |
| Net Unrealised Gain on Financial Futures Contracts | | | _ | 313,925 | 0.49 |

Lupus alpha All Opportunities Fund Schedule of investments and other net assets As at 31 December 2024

Contracts for Difference

| | | | | | Market Value | % of Net |
|-------------------|---|----------|---------------------|-----------|-----------------|----------|
| Country | Security Description | Currency | Holdings Cou | nterparty | EUR | Assets |
| Austria | Lenzing AG | EUR | (15,000) | UBS | 13,500 | 0.02 |
| Belgium | Azelis Group NV | EUR | 24,000 | UBS | 3,840 | 0.01 |
| Germany | Sixt SE | EUR | 8,000 | UBS | 71,600 | 0.11 |
| Italy | Danieli & C Officine Meccaniche SpA | EUR | 50,000 | UBS | 8,000 | 0.01 |
| Italy | Ferrari NV | EUR | (3,000) | UBS | 36,300 | 0.06 |
| Italy | Industrie De Nora SpA | EUR | (50,000) | UBS | 20,750 | 0.03 |
| Netherlands | Wolters Kluwer NV | EUR | (4,500) | UBS | 15,075 | 0.02 |
| Spain | Amadeus IT Group SA | EUR | (15,000) | UBS | 18,600 | 0.03 |
| Sweden | Alleima AB | SEK | (75,000) | UBS | 24,534 | 0.04 |
| Switzerland | Geberit AG | CHF | (1,500) UBS | | 60,883 | 0.10 |
| Total Market Valu | | | _ | 273,082 | 0.43 | |
| | | | | _ | | |
| Austria | ANDRITZ AG | EUR | 17,500 | UBS | (9,100) | (0.01) |
| Canada | First Majestic Silver Corp. | USD | 80,000 | UBS | (67,819) | (0.11) |
| Canada | Pan American Silver Corp. | USD | 22,000 | UBS | (56,799) | (0.09) |
| Germany | Beiersdorf AG | EUR | (5,000) | UBS | (7,000) | (0.01) |
| Luxembourg | APERAM SA | EUR | 25,000 | UBS | (46,500) | (0.07) |
| Spain | CIE Automotive SA | EUR | (20,000) | UBS | (10,000) | (0.02) |
| Turkiye | Eldorado Gold Corp. | USD | 50,000 | UBS | (73,696) | (0.12) |
| Total Market Valu | e on Contracts for Difference - Liabilities | | | _ | (270,914) | (0.43) |
| Net Market Value | on Contracts for Difference - Assets | | | _ | 2,168 | |

The accompanying notes are an integral part of the Financial Statements

Lupus alpha Global Convertible Bonds Schedule of investments and other net assets As at 31 December 2024

| Convertible Bonds | Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|--|------------------------|----------------------------|------------------------|-----------------|
| Australia Telix Pharmaceuticals Ltd., Reg. S 2.375% 30/07/2029 AUD 200,000 147,253 0.46 147,253 0.46 0.40 China China USD 950,000 215,784 0.68 0.68 0.68 0.06 3.06 0.68 0.06 0.06 Xiaomi Best Time International Ltd., Reg. S 0% 17/12/2027 USD 950,000 215,784 0.68 0.06 0.06 0.06 0.06 France EUR 400,000 226,343 0.71 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.0 | Transferable securities and money market instruments admitted to an off | icial exchange listing | g | | |
| Telix Pharmaceuticals Ltd., Reg. S 2.375% 30/07/2029 | Convertible Bonds | | | | |
| China Alibaba Group Holding Ltd., 144A 0.5% 01/06/2031 USD 950,000 971,553 3.06 Xiaomi Best Time International Ltd., Reg. S 0% 17/12/2027 USD 200,000 215,784 0.68 France Accor SA, Reg. S 0.7% 07/12/2027 EUR 400,000 226,343 0.71 BNP Paribas SA, Reg. S 0% 13/05/2025 EUR 200,000 235,556 0.74 Elis SA, Reg. S 2% 07/02/2031 EUR 400,000 371,528 1.17 SPIE SA, Reg. S 2.65% 27/03/2026 EUR 200,000 235,556 0.74 Wendel SE, Reg. S 2.65% 27/03/2026 EUR 200,000 371,528 1.17 SWendel SE, Reg. S 2.65% 27/03/2026 EUR 300,000 205,415 0.65 Germany Bechtle AG, Reg. S 2% 08/12/2030 EUR 300,000 285,870 0.90 LEG Properties BV, Reg. S 1% 04/09/2030 EUR 300,000 204,362 0.44 Rein SpA, Reg. S 2.875% 11/09/2039 EUR 300,000 306,024 0.96 | | AUD | 200,000_ | 147,253 | 0.46 |
| Alibaba Group Holding Ltd., 144A 0.5% 01/06/2031 USD 950,000 971,553 3.06 Xiaomi Best Time International Ltd., Reg. S 0% 17/12/2027 USD 200,000 215,784 0.68 1,187,337 3.74 France Accor SA, Reg. S 0.7% 07/12/2027 EUR 400,000 226,343 0.71 EIB SAP Paribas SA, Reg. S 0% 13/05/2025 EUR 200,000 235,556 0.74 EIB SA, Reg. S 2.25% 22/09/2029 EUR 100,000 130,396 0.41 Orpar SA, Reg. S 2.25% 22/09/2029 EUR 100,000 371,528 1.17 SPIE SA, Reg. S 2% 07/02/2031 EUR 200,000 219,207 0.69 Wendel SE, Reg. S 2.625% 27/03/2026 EUR 200,000 206,415 0.65 1.389,445 4.37 France Bechile AG, Reg. S 2.625% 27/03/2026 EUR 300,000 285,870 0.90 EUR 9.000 200,415 0.65 1.389,445 0.65 1 | | | | 147,253 | 0.46 |
| Alibaba Group Holding Ltd., 144A 0.5% 01/06/2031 USD 950,000 971,553 3.06 Xiaomi Best Time International Ltd., Reg. S 0% 17/12/2027 USD 200,000 215,784 0.68 1,187,337 3.74 France Accor SA, Reg. S 0.7% 07/12/2027 EUR 400,000 226,343 0.71 EIB SAP Paribas SA, Reg. S 0% 13/05/2025 EUR 200,000 235,556 0.74 EIB SA, Reg. S 2.25% 22/09/2029 EUR 100,000 130,396 0.41 Orpar SA, Reg. S 2.25% 22/09/2029 EUR 100,000 371,528 1.17 SPIE SA, Reg. S 2% 07/02/2031 EUR 200,000 219,207 0.69 Wendel SE, Reg. S 2.625% 27/03/2026 EUR 200,000 206,415 0.65 1.389,445 4.37 France Bechile AG, Reg. S 2.625% 27/03/2026 EUR 300,000 285,870 0.90 EUR 9.000 200,415 0.65 1.389,445 0.65 1 | China | | | | |
| 1,187,37 3,74 | | USD | 950,000 | 971,553 | 3.06 |
| France | Xiaomi Best Time International Ltd., Reg. S 0% 17/12/2027 | USD | 200,000 | 215,784 | 0.68 |
| Accor SA, Reg. S 0.7% 07/12/2027 EUR 400,000 226,343 0.71 | | | | 1,187,337 | 3.74 |
| Accor SA, Reg. S 0.7% 07/12/2027 EUR 400,000 226,343 0.71 | France | | | | |
| BNP Paribas SA, Reg. S 0% 13/05/2025 EUR 200,000 235,556 0.74 | | EUR | 400.000 | 226.343 | 0.71 |
| Elis SA, Reg. S 2.25% 22/09/2029 EUR 100,000 130,396 0.41 Orpar SA, Reg. S 29% 07/02/2031 EUR 400,000 371,528 1.17 SPIE SA, Reg. S 29% 17/01/2028 EUR 200,000 219,207 0.69 Wendel SE, Reg. S 2.625% 27/03/2026 EUR 200,000 206,415 0.65 1,389,445 4.37 Organisms | | | , | * | |
| Orpar SA, Reg. S 2% 07/02/2031 EUR 400,000 371,528 1.17 SPIE SA, Reg. S 2% 17/01/2028 EUR 200,000 219,207 0.69 Wendel SE, Reg. S 2.625% 27/03/2026 EUR 200,000 206,415 0.65 I,389,445 4.37 Germany Bechtle AG, Reg. S 2% 08/12/2030 EUR 300,000 285,870 0.90 LEG Properties BV, Reg. S 1% 04/09/2030 EUR 600,000 615,836 1.94 Rheinmetall AG, Reg. S 2.25% 07/02/2030 EUR 100,000 204,462 0.64 Italy EII SpA, Reg. S 2.95% 14/09/2030 EUR 300,000 306,024 0.96 Saipem SpA, Reg. S 2.875% 11/09/2029 EUR 100,000 144,416 0.46 Japan 450,440 1.42 ANA Holdings, Inc., Reg. S 0% 10/12/2031 JPY 70,000,000 469,722 1.48 Resonac Holdings Corp., Reg. S 0% 25/07/2031 JPY 50,000,000 351,985 1.10 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR | | | | | |
| SPIE SA, Reg. S 2% 17/01/2028 EUR 200,000 219,207 0.69 Wendel SE, Reg. S 2.625% 27/03/2026 EUR 200,000 206,415 0.65 1,389,445 4.37 Germany | —————————————————————————————————————— | | | | |
| Wendel SE, Reg. S 2.625% 27/03/2026 EUR 200,000 206,415 0.65 I,389,445 4.37 Germany Bechtle AG, Reg. S 2% 08/12/2030 EUR 300,000 285,870 0.90 LEG Properties BV, Reg. S 1% 04/09/2030 EUR 600,000 615,836 1.94 Rheinmetall AG, Reg. S 2.25% 07/02/2030 EUR 100,000 204,462 0.64 Ltaly EIIS SpA, Reg. S 2.95% 14/09/2030 EUR 300,000 306,024 0.96 Saipem SpA, Reg. S 2.875% 11/09/2029 EUR 100,000 144,416 0.46 ANA Holdings, Inc., Reg. S 0% 10/12/2031 JPY 70,000,000 469,722 1.48 Resonae Holdings Corp., Reg. S 0% 29/12/2028 JPY 50,000,000 351,985 1.10 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | · · | | | | 0.69 |
| Germany Bechtle AG, Reg. S 2% 08/12/2030 EUR 300,000 285,870 0.90 LEG Properties BV, Reg. S 19% 04/09/2030 EUR 600,000 615,836 1.94 Rheinmetall AG, Reg. S 2.25% 07/02/2030 EUR 100,000 204,462 0.64 Italy EIIS SPA, Reg. S 2.95% 14/09/2030 EUR 300,000 306,024 0.96 Saipem SpA, Reg. S 2.875% 11/09/2029 EUR 100,000 144,416 0.46 Japan ANA Holdings, Inc., Reg. S 0% 10/12/2031 JPY 70,000,000 469,722 1.48 Resonac Holdings Corp., Reg. S 0% 29/12/2028 JPY 50,000,000 351,985 1.10 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | <u> </u> | | | | 0.65 |
| Bechtle AG, Reg. S 2% 08/12/2030 EUR 300,000 285,870 0.90 LEG Properties BV, Reg. S 1% 04/09/2030 EUR 600,000 615,836 1.94 Rheinmetall AG, Reg. S 2.25% 07/02/2030 EUR 100,000 204,462 0.64 Italy Eni SpA, Reg. S 2.95% 14/09/2030 EUR 300,000 306,024 0.96 Saipem SpA, Reg. S 2.875% 11/09/2029 EUR 100,000 144,416 0.46 Japan ANA Holdings, Inc., Reg. S 0% 10/12/2031 JPY 70,000,000 469,722 1.48 Resonac Holdings Corp., Reg. S 0% 29/12/2028 JPY 50,000,000 351,985 1.10 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | - | | _ | 1,389,445 | 4.37 |
| Bechtle AG, Reg. S 2% 08/12/2030 EUR 300,000 285,870 0.90 LEG Properties BV, Reg. S 1% 04/09/2030 EUR 600,000 615,836 1.94 Rheinmetall AG, Reg. S 2.25% 07/02/2030 EUR 100,000 204,462 0.64 Italy Eni SpA, Reg. S 2.95% 14/09/2030 EUR 300,000 306,024 0.96 Saipem SpA, Reg. S 2.875% 11/09/2029 EUR 100,000 144,416 0.46 Japan ANA Holdings, Inc., Reg. S 0% 10/12/2031 JPY 70,000,000 469,722 1.48 Resonac Holdings Corp., Reg. S 0% 29/12/2028 JPY 50,000,000 351,985 1.10 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | | | | | _ |
| LEG Properties BV, Reg. S 1% 04/09/2030 EUR 600,000 615,836 1.94 Rheinmetall AG, Reg. S 2.25% 07/02/2030 EUR 100,000 204,462 0.64 Italy Eni SpA, Reg. S 2.95% 14/09/2030 EUR 300,000 306,024 0.96 Saipem SpA, Reg. S 2.875% 11/09/2029 EUR 100,000 144,416 0.46 Japan ANA Holdings, Inc., Reg. S 0% 10/12/2031 JPY 70,000,000 469,722 1.48 Resonac Holdings Corp., Reg. S 0% 29/12/2028 JPY 50,000,000 351,985 1.10 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | · | EUR | 300.000 | 285.870 | 0.90 |
| Rheinmetall AG, Reg. S 2.25% 07/02/2030 EUR 100,000 204,462 0.64 1,106,168 3.48 | · · · · · · · · · · · · · · · · · · · | | | | |
| Italy Eni SpA, Reg. S 2.95% 14/09/2030 EUR 300,000 306,024 0.96 Saipem SpA, Reg. S 2.875% 11/09/2029 EUR 100,000 144,416 0.46 Japan ANA Holdings, Inc., Reg. S 0% 10/12/2031 JPY 70,000,000 469,722 1.48 Resonac Holdings Corp., Reg. S 0% 29/12/2028 JPY 50,000,000 351,985 1.10 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | | | | | |
| Eni SpA, Reg. S 2.95% 14/09/2030 Saipem SpA, Reg. S 2.875% 11/09/2029 EUR 100,000 144,416 0.46 450,440 1.42 Japan ANA Holdings, Inc., Reg. S 0% 10/12/2031 Resonac Holdings Corp., Reg. S 0% 29/12/2028 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | , , | | , <u> </u> | | 3.48 |
| Eni SpA, Reg. S 2.95% 14/09/2030 Saipem SpA, Reg. S 2.875% 11/09/2029 EUR 100,000 144,416 0.46 450,440 1.42 Japan ANA Holdings, Inc., Reg. S 0% 10/12/2031 Resonac Holdings Corp., Reg. S 0% 29/12/2028 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | | | _ | | |
| Saipem SpA, Reg. S 2.875% 11/09/2029 EUR 100,000 144,416 0.46 Japan ANA Holdings, Inc., Reg. S 0% 10/12/2031 JPY 70,000,000 469,722 1.48 Resonac Holdings Corp., Reg. S 0% 29/12/2028 JPY 50,000,000 351,985 1.10 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | , and the second | EUR | 300.000 | 306.024 | 0.96 |
| Japan ANA Holdings, Inc., Reg. S 0% 10/12/2031 JPY 70,000,000 469,722 1.48 Resonac Holdings Corp., Reg. S 0% 29/12/2028 JPY 50,000,000 351,985 1.10 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | | | | | |
| ANA Holdings, Inc., Reg. S 0% 10/12/2031 Resonac Holdings Corp., Reg. S 0% 29/12/2028 SBI Holdings, Inc., Reg. S 0% 25/07/2031 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 JPY 70,000,000 469,722 1.48 1.10 50,000,000 266,391 0.84 1,088,098 3.42 | | | | | |
| ANA Holdings, Inc., Reg. S 0% 10/12/2031 Resonac Holdings Corp., Reg. S 0% 29/12/2028 SBI Holdings, Inc., Reg. S 0% 25/07/2031 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 JPY 70,000,000 469,722 1.48 1.10 50,000,000 266,391 0.84 1,088,098 3.42 | | | _ | | |
| Resonac Holdings Corp., Reg. S 0% 29/12/2028 JPY 50,000,000 351,985 1.10 SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 1,088,098 3.42 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 October 10.000 195,346 0.61 Description: | | JPY | 70,000.000 | 469.722 | 1.48 |
| SBI Holdings, Inc., Reg. S 0% 25/07/2031 JPY 40,000,000 266,391 0.84 1,088,098 3.42 Netherlands Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | | | | | |
| Netherlands EUR 200,000 195,346 0.61 | | | | | |
| Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | | | _ | 1,088,098 | 3.42 |
| Redcare Pharmacy NV, Reg. S 0% 21/01/2028 EUR 200,000 195,346 0.61 | | | _ | | |
| | | EUR | 200,000 | 195,346 | 0.61 |
| | | | , · · <u></u> | | |

The accompanying notes are an integral part of the Financial Statements

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|--------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an official | al exchange listin | g (continued) | | |
| Convertible Bonds (continued) | | | | |
| Singapore | | | | |
| Singapore Airlines Ltd., Reg. S 1.625% 03/12/2025 | SGD | 250,000 | 234,120 | 0.74 |
| STMicroelectronics NV, Reg. S 0% 04/08/2027 | USD | 400,000_ | 366,446 | 1.15 |
| | | | 600,566 | 1.89 |
| South Africa | | | | |
| Stillwater Mining Co., Reg. S 4.25% 28/11/2028 | USD | 200,000 | 179,640 | 0.57 |
| | | _ | 179,640 | 0.57 |
| Spain | | | | |
| Amadeus IT Group SA, Reg. S 1.5% 09/04/2025 | EUR | 100,000 | 127,144 | 0.40 |
| Cellnex Telecom SA, Reg. S 0.5% 05/07/2028 | EUR | 300,000 | 310,995 | 0.98 |
| | | | 438,139 | 1.38 |
| Sweden | | | | |
| Fastighets AB Balder, Reg. S 3.5% 23/02/2028 | EUR | 100,000 | 125,511 | 0.40 |
| | | _ | 125,511 | 0.40 |
| Taiwan | | | | |
| Globalwafers GmbH, Reg. S 1.5% 23/01/2029 | EUR | 200,000 | 186,671 | 0.59 |
| | | _ | 186,671 | 0.59 |
| United Kingdom | | | | |
| International Consolidated Airlines Group SA, Reg. S 1.125% | ELID | 300,000 | 271 110 | 1 17 |
| 18/05/2028 | EUR | 300,000_ | 371,118 | 1.17 |
| | | _ | 371,118 | 1.17 |
| United States of America | Hab | 200,000 | 222.554 | 0.72 |
| Goldman Sachs Finance Corp. International Ltd. 0% 15/03/2027 Merrill Lynch BV, Reg. S 0% 30/01/2026 | USD EUR | 200,000 500,000 | 233,554 493,492 | 0.73 1.55 |
| Repligen Corp. 1% 15/12/2028 | USD | 200,000 | 197,389 | 0.62 |
| Schneider Electric SE, Reg. S 1.97% 27/11/2030 | EUR | 200,000 | 254,076 | 0.80 |
| Schneider Electric SE, Reg. S 1.625% 28/06/2031 | EUR | 200,000 | 212,589 | 0.67 |
| Simon Global Development BV, Reg. S 3.5% 14/11/2026 | EUR | 200,000 | 217,766 | 0.69 |
| | | _ | 1,608,866 | 5.06 |
| Total Convertible Bonds | | | 9,074,598 | 28.56 |
| | | | , , | |

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|-------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments admitted to an officia | l exchange listin | g (continued) | | |
| Equities | | | | |
| United States of America | | | | |
| Bank of America Corp. Preference 7.25% | USD | 750 | 881,244 | 2.77 |
| | | _ | 881,244 | 2.77 |
| Total Equities | | <u> </u> | 881,244 | 2.77 |
| Total Transferable securities and money market instruments admitted to an o | official exchange | e listing | 9,955,842 | 31.33 |
| Transferable securities and money market instruments dealt in on another re- | gulated market | | | |
| Convertible Bonds | | | | |
| China | | | | |
| JD.com, Inc., 144A 0.25% 01/06/2029 | USD | 450,000 | 459,618 | 1.44 |
| Lenovo Group Ltd., Reg. S 2.5% 26/08/2029 | USD | 300,000 | 377,727 | 1.19 |
| Li Auto, Inc. 0.25% 01/05/2028 | USD | 575,000 | 639,089 | 2.01 |
| Ping An Insurance Group Co. of China Ltd., Reg. S 0.875% 22/07/2029 | USD | 600,000 | 701,316 | 2.21 |
| Trip.com Group Ltd., 144A 0.75% 15/06/2029 | USD | 400,000 | 472,424 | 1.49 |
| ZTO Express Cayman, Inc. 1.5% 01/09/2027 | USD | 200,000 | 190,694 | 0.60 |
| | | _ | 2,840,868 | 8.94 |
| Japan | | | | |
| Daifuku Co. Ltd., Reg. S 0% 13/09/2030 | JPY | 40,000,000 | 293,293 | 0.93 |
| | | | 293,293 | 0.93 |
| Macau | | | | |
| Wynn Macau Ltd., 144A 4.5% 07/03/2029 | USD | 400,000 | 385,131 | 1.21 |
| | | _ | 385,131 | 1.21 |
| Singapore | | 4.50.000 | 404040 | 0.70 |
| Sea Ltd. 2.375% 01/12/2025 | USD | 150,000 | 184,818 | 0.58 |
| | | | 184,818 | 0.58 |
| South Korea | Hab | 200.000 | 260 421 | 0.05 |
| LG Chem Ltd., Reg. S 1.6% 18/07/2030 | USD | 300,000 | 269,431 | 0.85 |
| | | _ | 269,431 | 0.85 |
| Taiwan Gigabyte Technology Co. Ltd., Reg. S 0% 27/07/2028 | USD | 200,000 | 200,999 | 0.63 |
| Cigacyte Technology Co. Eta., Reg. 5 070 2710712020 | CDD | 200,000 | 200,777 | 0.03 |

| Convertible Bonds (continued) Favorage | Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|--|-------------------|----------------------------|------------------------|-----------------|
| Taiwan (continued) USD 200,000 218,153 0.69 United States of America Advanced Energy Industries, Inc. 2.5% 1509/2028 USD 250,000 262,873 0.83 Akamai Technologies, Inc. 0.125% 01/05/2025 USD 250,000 262,873 0.83 Akamai Technologies, Inc. 0.375% 01/09/2027 USD 250,000 262,873 0.83 Almylam Pharmaceuticals, Inc. 1% 15/09/2027 USD 250,000 269,461 1.98 Almylam Pharmaceutical, Inc. 1.5% 01/07/2025 USD 300,000 256,870 0.81 American Matthes Group, Inc. 6.5% 01/07/2025 USD 300,000 191,128 0.60 BILL Holdings, Inc., 144A 0% 01/04/2030 USD 200,000 191,128 0.60 BILL Holdings, Inc., 144A 1% 01/06/2029 USD 200,000 179,532 0.56 BlackLine, Inc., 144A 1% 01/06/2029 USD 300,000 313,429 0.99 CMS Energy Corp, 3.375% 01/06/2028 USD 250,000 250,900 0.79 Corbiases Global, Inc., 144A 1% 01/06/2029 USD 250,000 187,201 | Transferable securities and money market instruments dealt in on another r | egulated market (| (continued) | | |
| Hon Hai Precision Industry Co. Ltd., Reg. S 0% 05/08/2026 USD 200,000 419,152 1.32 | Convertible Bonds (continued) | | | | |
| United States of America 419,152 1.32 Advanced Energy Industries, Inc. 2.5% 15/09/2028 USD 250,000 262,873 0.83 Akamai Technologies, Inc. 0.125% 01/05/2025 USD 550,000 224,807 0.64 Akamai Technologies, Inc. 0.125% 01/09/2027 USD 550,000 629,461 1.98 Alnylam Pharmaceuticals, Inc. 19 15/09/2027 USD 250,000 256,870 0.81 American Airlines Group, Inc. 6.5% 01/07/2025 USD 200,000 191,128 0.60 BILL Holdings, Inc. 144A 0% 01/04/2030 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc. 125% 15/05/2027 USD 200,000 179,532 0.56 Black Line, Inc., 144A 19 6 01/06/2029 USD 200,000 179,532 0.56 Black Line, Inc., 144A 80 6 1/06/2028 USD 250,000 179,532 0.56 Coinbase Ghola, Inc., 144A 0 0.25% 01/04/2030 USD 250,000 179,532 0.56 Core Scientifie, Inc., 144A 19 0.11/12/2029 USD 150,000 187,201 0.59 Cytokinetics, Inc | Taiwan (continued) | | | | |
| United States of America Advanced Energy Industries, Inc. 2.5% 15/09/2028 Akamai Technologies, Inc. 0.125% 01/05/2025 USD 200,000 204,807 0.64 Akamai Technologies, Inc. 0.375% 01/09/2027 USD 250,000 256,870 0.81 Alnylam Pharmaceuticials, Inc. 1% 15/09/2027 USD 250,000 340,943 1.07 American Airlines Group, Inc. 6.5% 01/07/2025 USD 300,000 340,943 1.07 American Airlines Group, Inc. 6.5% 01/07/2025 USD 200,000 191,128 0.60 BILL Holdings, Inc., 144A 0% 01/04/2030 USD 200,000 191,128 0.60 Bild Holdings, Inc., 144A 0 % 01/04/2030 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 200,000 179,532 0.56 BlackLine, Inc., 144A 1% 01/06/2029 USD 300,000 313,429 0.59 CMS Energy Corp. 3.375% 01/05/2028 USD 250,000 250,500 0.79 Coinbase Global, Inc., 144A 0.85% 01/04/2030 USD 450,000 469,849 1.48 Core Scientific, Inc., 144A 0% 15/06/2031 USD 200,000 187,201 0.59 Cytokinetics, Inc. 3.5% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 172,318 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 188,445 0.62 Dropbox, Inc. 09 01/03/2028 USD 200,000 188,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 300,000 315,105 0.99 FirstEnergy Corp. 4.125% 15/04/2026 USD 300,000 188,449 0.62 Dropbox, Inc. 09 01/03/2028 USD 200,000 188,449 0.62 Dropbox, Inc. 09 01/03/2026 USD 300,000 315,105 0.99 FirstEnergy Corp. 4.125% 15/04/2026 USD 800,000 74,555 0.35 Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 HAT Holdings I LLC, 144A 3.75% 15/08/2038 USD 250,000 268,544 1.35 Ionis Pharmaceuticals, Inc. 18 15/08/2028 USD 350,000 268,544 Insulet Corp. 0.375% 01/09/2026 USD 300,000 318,881 1.00 MARA Holdings, Inc., 144A 0.75% 01/06/2030 USD 350,000 268,544 0.85 Middleby Corp. (The) 1440 0.75% 01/06/2030 USD 200,000 196,645 0.62 Micochird Federalogy, Inc., 144A 0.75% 01/06/2030 USD 200,000 269,712 | Hon Hai Precision Industry Co. Ltd., Reg. S 0% 05/08/2026 | USD | 200,000 | 218,153 | 0.69 |
| Advanced Energy Industries, Inc. 2.5% 15/09/2025 Akamai Technologies, Inc. 0.125% 01/05/2025 USD 200,000 204,807 0.64 Akamai Technologies, Inc. 0.375% 01/09/2027 USD 650,000 629,461 1.98 Alnylam Pharmaceuticals, Inc. 1% 15/09/2027 USD 250,000 256,870 0.81 American Airlines Group, Inc. 6.5% 01/07/2025 USD 300,000 340,943 1.07 American Airlines Group, Inc. 6.5% 01/07/2025 USD 200,000 191,128 0.60 BILL Holdings, Inc., 144A 0% 01/04/2030 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 300,000 313,429 0.99 CMS Energy Corp. 3.375% 01/05/2028 USD 300,000 313,429 0.99 CMS Energy Corp. 3.375% 01/05/2028 USD 450,000 250,500 0.79 Coinbase Global, Inc., 144A 0% 51/04/2030 USD 450,000 187,201 0.59 Cytokinetics, Inc. 3.5% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 173,091 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 200,000 198,454 Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 198,459 0.62 Dropbox, Inc. 0.60 01/03/2028 USD 200,000 198,459 0.62 Dropbox, Inc. 0.60 01/03/2026 USD 300,000 315,105 Duke Energy Corp. 4.125% 15/04/2026 USD 300,000 315,105 Duke Energy Corp. 4.125% 15/04/2026 USD 500,000 315,105 Duke Theory Corp. 48 01/05/2026 USD 500,000 198,449 0.62 Ford Motor Co. 0% 15/03/2026 USD 500,000 315,105 Guidewire Software, Inc., 144A 1.5% 01/03/2031 USD 500,000 315,005 Guidewire Software, Inc., 144A 1.5% 01/03/2031 USD 500,000 315,005 Jis. 103 Jis. 105 Jis. 106 Jis. 200,000 315,005 Jis. 300,000 315,005 Jis. 3 | | | | 419,152 | 1.32 |
| Advanced Energy Industries, Inc. 2.5% 15/09/2025 Akamai Technologies, Inc. 0.125% 01/05/2025 USD 200,000 204,807 0.64 Akamai Technologies, Inc. 0.375% 01/09/2027 USD 650,000 629,461 1.98 Alnylam Pharmaceuticals, Inc. 1% 15/09/2027 USD 250,000 256,870 0.81 American Airlines Group, Inc. 6.5% 01/07/2025 USD 300,000 340,943 1.07 American Airlines Group, Inc. 6.5% 01/07/2025 USD 200,000 191,128 0.60 BILL Holdings, Inc., 144A 0% 01/04/2030 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 300,000 313,429 0.99 CMS Energy Corp. 3.375% 01/05/2028 USD 300,000 313,429 0.99 CMS Energy Corp. 3.375% 01/05/2028 USD 450,000 250,500 0.79 Coinbase Global, Inc., 144A 0% 51/04/2030 USD 450,000 187,201 0.59 Cytokinetics, Inc. 3.5% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 173,091 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 200,000 198,454 Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 198,459 0.62 Dropbox, Inc. 0.60 01/03/2028 USD 200,000 198,459 0.62 Dropbox, Inc. 0.60 01/03/2026 USD 300,000 315,105 Duke Energy Corp. 4.125% 15/04/2026 USD 300,000 315,105 Duke Energy Corp. 4.125% 15/04/2026 USD 500,000 315,105 Duke Theory Corp. 48 01/05/2026 USD 500,000 198,449 0.62 Ford Motor Co. 0% 15/03/2026 USD 500,000 315,105 Guidewire Software, Inc., 144A 1.5% 01/03/2031 USD 500,000 315,005 Guidewire Software, Inc., 144A 1.5% 01/03/2031 USD 500,000 315,005 Jis. 103 Jis. 105 Jis. 106 Jis. 200,000 315,005 Jis. 300,000 315,005 Jis. 3 | United States of America | | | | |
| Akamai Technologies, Inc. 0.125% 01/05/2025 Akamai Technologies, Inc. 0.375% 01/09/2027 USD 550,000 629,461 1.98 Alnylam Pharmaceuticals, Inc. 19 15/09/2027 USD 250,000 256,870 0.81 American Airlines Group, Inc. 6.5% 01/07/2025 USD 300,000 340,943 1.07 American Water Capital Corp. 3.625% 15/06/2026 USD 200,000 191,128 0.60 BILL Holdings, Inc., 144A 0% 01/04/2030 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 200,000 179,532 0.56 BlackLine, Inc., 144A 0% 01/04/2039 USD 300,000 313,429 0.99 CMS Energy Corp. 3.375% 01/05/2028 USD 300,000 250,590 0.79 Coinbase Global, Inc., 144A 0.75% 01/04/2030 USD 450,000 469,849 1.48 Core Scientific, Inc., 144A 0% 15/06/2031 USD 200,000 187,201 0.59 Cytokinetics, Inc. 3.5% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 172,318 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,545 0.62 Dropbox, Inc. 0.375% 15/05/2028 USD 200,000 198,545 0.62 Dropbox, Inc. 0.96 01/03/2028 USD 200,000 198,545 0.62 Dropbox, Inc. 0.96 01/03/2026 USD 300,000 315,105 0.99 FirstEnergy Corp. 4.125% 15/04/2026 USD 300,000 315,105 Devery, Inc. 4.5% 15/12/2027 USD 550,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 500,000 198,449 0.62 Dike Energy Corp. 4.125% 15/04/2026 USD 500,000 315,105 Devery, Inc. 4.5% 15/12/2027 USD 500,000 315,105 Devery Inc. 144A 0.5% 01/03/2031 USD 500,000 315,105 Devery Inc. 4.5% 15/12/2027 USD 500,000 315,105 Devery Inc. 4.5% 15/12/2027 USD 500,000 315,105 Devery Inc. 4.5% 15/12/2026 USD 500,000 318,881 I.68 Ford Motor Co. 0% 15/03/2026 USD 500,000 318,881 I.68 Ford Motor Co. 0% 15/03/2026 USD 500,000 318,881 I.69 Ford Motor Co. 0% 15/03/2026 USD 300,000 318,881 I.60 Ford Motor Co. 0% 15/03/2026 USD 300,000 318,881 I.60 Ford Motor Co. 0% 15/03/2026 USD 300,000 318,881 I.60 Ford Motor Co. 0% 15/03/2026 USD 300,000 318,881 I.60 Ford Motor Co. 0% 15/03/2026 USD 300,000 318,881 I.60 Ford Motor Co. 0% 15/03/2026 USD 300,00 | * | HSD | 250,000 | 262 873 | 0.83 |
| Akamai Technologies, Inc. 0.375% 01/09/2027 USD 550,000 629,461 1.98 Alnylam Pharmaceuticals, Inc. 1% 15/09/2027 USD 250,000 256,870 0.81 American Airlines Group, Inc. 6.5% 01/07/2025 USD 300,000 340,943 1.07 American Water Capital Corp. 3.625% 15/06/2026 USD 200,000 191,128 0.60 BILL Holdings, Inc., 144A 0% 01/04/2030 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 200,000 179,532 0.56 BiackLine, Inc., 144A 1% 01/06/2029 USD 300,000 313,429 0.99 CMS Energy Corp. 3.375% 01/05/2028 USD 300,000 250,590 0.79 Coinbase Global, Inc., 144A 0.25% 01/04/2030 USD 450,000 250,590 0.79 Coinbase Global, Inc., 144A 0.87 10/40/2031 USD 200,000 187,201 0.59 Cytokinetics, Inc. 3.5% 01/07/2027 USD 200,000 187,201 0.59 Cytokinetics, Inc. 3.5% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 150,000 9,351 0.03 Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 173,091 0.54 Deigital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,459 0.62 Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 325,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 550,000 518,978 Global Payments, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 18 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings I LLC, 144A 3.75% 15/09/2030 USD 350,000 318,881 1.00 MARA Holdings, Inc., 144A 3.125% 15/09/2030 USD 350,000 318,881 1.00 MARA Holdings, Inc., 144A 0.625% 15/09/2030 USD 300,000 318,881 1.00 MARA Holdings, Inc., 144A 0.625% 15/09/2028 USD 200,000 265,161 0.83 Lumentum Holdings, Inc., 144A 3.06 01/06/2031 USD 350,000 243,388 0.77 Meritage Homes Corp., 144A 1.75% 15/09/2039 USD 200,000 265,643 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 200,000 156,623 0.84 Middleby Corp. (The) 1% 01/09/2025 | | | | | |
| Alnylam Pharmaceuticals, Inc. 1% 15/09/2027 | | | | | |
| American Airlines Group, Inc. 6.5% 01/07/2025 USD 300,000 340,943 1.07 American Water Capital Corp. 3.625% 15/06/2026 USD 200,000 191,128 0.60 BILL Holdings, Inc., 144A 0% 01/04/2030 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 300,000 313,429 0.99 CMS Energy Corp. 3.375% 01/05/2028 USD 250,000 250,590 0.79 Coinbase Global, Inc., 144A 0.25% 01/04/2030 USD 450,000 469,849 1.48 Core Scientific, Inc., 144A 0% 15/06/2031 USD 200,000 187,201 0.59 Cytokinetics, Inc., 3.5% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 150,000 173,091 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,445 0.62 Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,445 0.62 Drys, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 | | | | | |
| American Water Capital Corp. 3.625% 15/06/2026 BILL Holdings, Inc., 144A 0% 01/04/2030 BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 300,000 313,429 0.99 CMS Energy Corp. 3.375% 01/05/2028 USD 250,000 250,590 0.79 Coinbase Global, Inc., 144A 0.80 10/06/2031 USD 450,000 469,849 1.48 Core Scientific, Inc., 144A 0.81 15/06/2031 USD 200,000 187,2318 0.59 Cytokinetics, Inc., 144A 0% 15/06/2031 USD 200,000 173,318 0.54 Datadog, Inc., 144A 0% 15/06/2031 USD 150,000 173,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 173,091 0.59 Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 173,091 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,545 0.62 Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 325,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2026 USD 550,000 513,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 550,000 513,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 550,000 513,548 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 HAT Holdings I LL.C, 144A 3.75% 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings I LL.C, 144A 3.15% 01/01/2029 USD 350,000 318,782 USD 300,000 318,881 Inc. 94 Halozyme Therapeutics, Inc. 18 15/08/2028 USD 150,000 266,925 0.82 HAT Holdings I LL.C, 144A 3.15% 15/08/2028 USD 350,000 265,161 0.83 Lumentum Holdings, Inc. 0.90 01/04/2026 USD 350,000 265,161 0.83 Lumentum Holdings, Inc. 0.90 10/04/2026 USD 300,000 318,881 Inc. 0.90 15/04/2029 USD 300,000 243,388 0.77 Meritage Homes Corp., 144A 1.75% 15/05/2028 USD 300,000 284,524 0.90 MicroStrategy, Inc., 144A 0.6258 15/09/2028 USD 150,000 266,626 0.88 Middleby Corp. (The) 1% 01/09/2025 | · · · · · · · · · · · · · · · · · · · | | | | |
| BILL Holdings, Inc., 144A 0% 01/04/2030 USD 200,000 192,143 0.60 BioMarin Pharmaceutical, Inc., 1.25% 15/05/2027 USD 200,000 179,532 0.56 BlackLine, Inc., 144A 1% 01/06/2029 USD 300,000 313,429 0.99 CMS Energy Corp. 3:375% 01/05/2028 USD 250,000 250,590 0.79 Coinbase Global, Inc., 144A 0.25% 01/04/2030 USD 450,000 469,849 1.48 Core Scientific, Inc., 144A 0.8 15/06/2031 USD 200,000 187,201 0.59 Cytokinetics, Inc. 3:5% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 200,000 173,091 0.54 Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 173,091 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 325,000 315,105 0.99 FirstEnergy Corp. 4.9 10/05/2026 USD 550,000 518,94 0.62 Evergy | A ** | | | | |
| BioMarin Pharmaceutical, Inc. 1.25% 15/05/2027 USD 200,000 179,532 0.56 | • • | | | | |
| BlackLine, Inc., 144A 1% 01/06/2029 | | | | | |
| CMS Energy Corp. 3.375% 01/05/2028 USD 250,000 250,590 0.79 Coinbase Global, Inc., 144A 0.25% 01/04/2030 USD 450,000 469,849 1.48 Core Scientific, Inc., 144A 0.15% 06/2031 USD 200,000 187,201 0.59 Cytokinetics, Inc. 3.5% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 9,351 0.03 Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 173,091 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,449 0.62 Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 320,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.25% 01/11/2029 <td></td> <td></td> <td></td> <td>,</td> <td></td> | | | | , | |
| Coinbase Global, Inc., 144A 0.25% 01/04/2030 USD 450,000 469,849 1.48 Core Scientific, Inc., 144A 0% 15/06/2031 USD 200,000 187,201 0.59 Cytokinetics, Inc., 15% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 9,351 0.03 Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 173,091 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,545 0.62 Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 325,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4.40 10/05/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.5% 01/03/2031 | | | | * | |
| Core Scientific, Inc., 144A 0% 15/06/2031 USD 200,000 187,201 0.59 Cytokinetics, Inc. 3.5% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 9,351 0.03 Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 173,091 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,449 0.62 Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 325,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4.8 01/03/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.5% 01/03/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08 | • • | | | | |
| Cytokinetics, Inc. 3.5% 01/07/2027 USD 150,000 172,318 0.54 Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 9,351 0.03 Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 173,091 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,545 0.62 Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 325,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.5% 01/03/2038 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08/2028 USD 150,000 138,782 0.44 Insulet Corp. 0.375% 01/09/2026 | | | | | |
| Datadog, Inc., 144A 0% 01/12/2029 USD 10,000 9,351 0.03 Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 173,091 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,545 0.62 Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 320,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.25% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings I LLC, 144A 3.75% 15/08/2028 USD 350,000 428,194 1.35 Ionis Pharmaceuticals, In | | | | | |
| Dexcom, Inc. 0.375% 15/05/2028 USD 200,000 173,091 0.54 Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,545 0.62 Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 325,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings I LLC, 144A 3.75% 15/08/2028 USD 125,000 138,782 0.44 Insulet Corp. 0.375% 01/09/2026 USD 350,000 428,194 1.35 Ionis Pharmaceuticals, Inc. | • | | | | |
| Digital Realty Trust LP, REIT, 144A 1.875% 15/11/2029 USD 200,000 198,545 0.62 Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 325,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings I LLC, 144A 3.75% 15/08/2028 USD 125,000 138,782 0.44 Insulet Corp. 0.375% 01/09/2026 USD 350,000 428,194 1.35 Ionis Pharmaceuticals, Inc. 0% 01/04/2026 USD 550,000 512,275 1.61 Jazz Investments | | | | | |
| Dropbox, Inc. 0% 01/03/2028 USD 200,000 198,449 0.62 Duke Energy Corp. 4.125% 15/04/2026 USD 325,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 19k 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings I LLC, 144A 3.75% 15/08/2028 USD 125,000 138,782 0.44 Insulet Corp. 0.375% 01/09/2026 USD 350,000 428,194 1.35 Ionis Pharmaceuticals, Inc. 0% 01/04/2026 USD 550,000 512,275 1.61 Jazz Investments I Ltd., 144A 3.125% 15/09/2030 USD 175,000 181,904 0.57 Live Nation Entertainm | | | | | |
| Duke Energy Corp. 4.125% 15/04/2026 USD 325,000 322,167 1.01 Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings I LLC, 144A 3.75% 15/08/2028 USD 125,000 138,782 0.44 Insulet Corp. 0.375% 01/09/2026 USD 350,000 428,194 1.35 Ionis Pharmaceuticals, Inc. 0% 01/04/2026 USD 550,000 512,275 1.61 Jazz Investments I Ltd., 144A 3.125% 15/09/2030 USD 175,000 181,904 0.57 Live Nation Entertainment, Inc. 3.125% 15/01/2029 USD 300,000 318,881 1.00 M | | | | | |
| Evergy, Inc. 4.5% 15/12/2027 USD 300,000 315,105 0.99 FirstEnergy Corp. 4% 01/05/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings LLC, 144A 3.75% 15/08/2028 USD 125,000 138,782 0.44 Insulet Corp. 0.375% 01/09/2026 USD 350,000 428,194 1.35 Ionis Pharmaceuticals, Inc. 0% 01/04/2026 USD 550,000 512,275 1.61 Jazz Investments I Ltd., 144A 3.125% 15/09/2030 USD 175,000 181,904 0.57 Live Nation Entertainment, Inc. 3.125% 15/01/2029 USD 300,000 265,161 0.83 Lumentum Holdings, Inc., 144A 0% 01/06/2031 USD 350,000 268,544 0.85 | • | | | | |
| FirstEnergy Corp. 4% 01/05/2026 USD 550,000 533,548 1.68 Ford Motor Co. 0% 15/03/2026 USD 800,000 747,555 2.35 Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings I LLC, 144A 3.75% 15/08/2028 USD 125,000 138,782 0.44 Insulet Corp. 0.375% 01/09/2026 USD 350,000 428,194 1.35 Ionis Pharmaceuticals, Inc. 0% 01/04/2026 USD 550,000 512,275 1.61 Jazz Investments I Ltd., 144A 3.125% 15/09/2030 USD 175,000 181,904 0.57 Live Nation Entertainment, Inc. 3.125% 15/01/2029 USD 300,000 265,161 0.83 Lumentum Holdings, Inc., 144A 0% 01/06/2031 USD 350,000 268,544 0.85 Merit Medical Systems, Inc., 144A 1.75% 15/05/2028 USD 300,000 243,388 0.77 | ** * | | | | |
| Ford Motor Co. 0% 15/03/2026 Global Payments, Inc., 144A 1.5% 01/03/2031 USD S50,000 S18,978 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08/2028 USD USD 125,000 138,782 0.44 Insulet Corp. 0.375% 01/09/2026 USD S50,000 S50,000 S60,925 USD S50,000 S60,925 USD S50,000 S60,925 USD S50,000 S60,925 USD S50,000 S60,925 S60,9 | | | | | |
| Global Payments, Inc., 144A 1.5% 01/03/2031 USD 550,000 518,978 1.63 Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings I LLC, 144A 3.75% 15/08/2028 USD 125,000 138,782 0.44 Insulet Corp. 0.375% 01/09/2026 USD 350,000 428,194 1.35 Ionis Pharmaceuticals, Inc. 0% 01/04/2026 USD 550,000 512,275 1.61 Jazz Investments I Ltd., 144A 3.125% 15/09/2030 USD 175,000 181,904 0.57 Live Nation Entertainment, Inc. 3.125% 15/01/2029 USD 200,000 265,161 0.83 Lumentum Holdings, Inc. 0.5% 15/12/2026 USD 300,000 318,881 1.00 MARA Holdings, Inc., 144A 0% 01/06/2031 USD 350,000 268,544 0.85 Merit Medical Systems, Inc., 144A 1.75% 15/05/2028 USD 300,000 243,388 0.77 Meritage Homes Corp., 144A 0.75% 01/06/2030 USD 220,000 195,645 | | | | | |
| Guidewire Software, Inc., 144A 1.25% 01/11/2029 USD 150,000 141,828 0.45 Halozyme Therapeutics, Inc. 1% 15/08/2028 USD 250,000 260,925 0.82 HAT Holdings I LLC, 144A 3.75% 15/08/2028 USD 125,000 138,782 0.44 Insulet Corp. 0.375% 01/09/2026 USD 350,000 428,194 1.35 Ionis Pharmaceuticals, Inc. 0% 01/04/2026 USD 550,000 512,275 1.61 Jazz Investments I Ltd., 144A 3.125% 15/09/2030 USD 175,000 181,904 0.57 Live Nation Entertainment, Inc. 3.125% 15/01/2029 USD 200,000 265,161 0.83 Lumentum Holdings, Inc. 0.5% 15/12/2026 USD 300,000 318,881 1.00 MARA Holdings, Inc., 144A 0% 01/06/2031 USD 350,000 268,544 0.85 Merit Medical Systems, Inc., 144A 3% 01/02/2029 USD 300,000 243,388 0.77 Meritage Homes Corp., 144A 1.75% 15/05/2028 USD 300,000 284,524 0.90 MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 | | | | | |
| Halozyme Therapeutics, Inc. 1% 15/08/2028USD250,000260,9250.82HAT Holdings I LLC, 144A 3.75% 15/08/2028USD125,000138,7820.44Insulet Corp. 0.375% 01/09/2026USD350,000428,1941.35Ionis Pharmaceuticals, Inc. 0% 01/04/2026USD550,000512,2751.61Jazz Investments I Ltd., 144A 3.125% 15/09/2030USD175,000181,9040.57Live Nation Entertainment, Inc. 3.125% 15/01/2029USD200,000265,1610.83Lumentum Holdings, Inc. 0.5% 15/12/2026USD300,000318,8811.00MARA Holdings, Inc., 144A 0% 01/06/2031USD350,000268,5440.85Merit Medical Systems, Inc., 144A 3% 01/02/2029USD200,000243,3880.77Meritage Homes Corp., 144A 1.75% 15/05/2028USD300,000284,5240.90Microchip Technology, Inc., 144A 0.75% 01/06/2030USD220,000195,6450.62MicroStrategy, Inc., 144A 0.625% 15/09/2028USD150,000266,2630.84Middleby Corp. (The) 1% 01/09/2025USD250,000269,7120.85 | • | | | | |
| HAT Holdings I LLC, 144A 3.75% 15/08/2028USD125,000138,7820.44Insulet Corp. 0.375% 01/09/2026USD350,000428,1941.35Ionis Pharmaceuticals, Inc. 0% 01/04/2026USD550,000512,2751.61Jazz Investments I Ltd., 144A 3.125% 15/09/2030USD175,000181,9040.57Live Nation Entertainment, Inc. 3.125% 15/01/2029USD200,000265,1610.83Lumentum Holdings, Inc. 0.5% 15/12/2026USD300,000318,8811.00MARA Holdings, Inc., 144A 0% 01/06/2031USD350,000268,5440.85Merit Medical Systems, Inc., 144A 3% 01/02/2029USD200,000243,3880.77Meritage Homes Corp., 144A 1.75% 15/05/2028USD300,000284,5240.90Microchip Technology, Inc., 144A 0.75% 01/06/2030USD220,000195,6450.62MicroStrategy, Inc., 144A 0.625% 15/09/2028USD150,000266,2630.84Middleby Corp. (The) 1% 01/09/2025USD250,000269,7120.85 | | | | | |
| Insulet Corp. 0.375% 01/09/2026 USD 350,000 428,194 1.35 Ionis Pharmaceuticals, Inc. 0% 01/04/2026 USD 550,000 512,275 1.61 Jazz Investments I Ltd., 144A 3.125% 15/09/2030 USD 175,000 181,904 0.57 Live Nation Entertainment, Inc. 3.125% 15/01/2029 USD 200,000 265,161 0.83 Lumentum Holdings, Inc. 0.5% 15/12/2026 USD 300,000 318,881 1.00 MARA Holdings, Inc., 144A 0% 01/06/2031 USD 350,000 268,544 0.85 Merit Medical Systems, Inc., 144A 3% 01/02/2029 USD 200,000 243,388 0.77 Meritage Homes Corp., 144A 1.75% 15/05/2028 USD 300,000 284,524 0.90 Microchip Technology, Inc., 144A 0.75% 01/06/2030 USD 220,000 195,645 0.62 MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | | | | | |
| Ionis Pharmaceuticals, Inc. 0% 01/04/2026 USD 550,000 512,275 1.61 Jazz Investments I Ltd., 144A 3.125% 15/09/2030 USD 175,000 181,904 0.57 Live Nation Entertainment, Inc. 3.125% 15/01/2029 USD 200,000 265,161 0.83 Lumentum Holdings, Inc. 0.5% 15/12/2026 USD 300,000 318,881 1.00 MARA Holdings, Inc., 144A 0% 01/06/2031 USD 350,000 268,544 0.85 Merit Medical Systems, Inc., 144A 3% 01/02/2029 USD 200,000 243,388 0.77 Meritage Homes Corp., 144A 1.75% 15/05/2028 USD 300,000 284,524 0.90 Microchip Technology, Inc., 144A 0.75% 01/06/2030 USD 220,000 195,645 0.62 MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | —————————————————————————————————————— | | * | | |
| Jazz Investments I Ltd., 144A 3.125% 15/09/2030 USD 175,000 181,904 0.57 Live Nation Entertainment, Inc. 3.125% 15/01/2029 USD 200,000 265,161 0.83 Lumentum Holdings, Inc. 0.5% 15/12/2026 USD 300,000 318,881 1.00 MARA Holdings, Inc., 144A 0% 01/06/2031 USD 350,000 268,544 0.85 Merit Medical Systems, Inc., 144A 3% 01/02/2029 USD 200,000 243,388 0.77 Meritage Homes Corp., 144A 1.75% 15/05/2028 USD 300,000 284,524 0.90 Microchip Technology, Inc., 144A 0.75% 01/06/2030 USD 220,000 195,645 0.62 MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | • | | | | |
| Live Nation Entertainment, Inc. 3.125% 15/01/2029 USD 200,000 265,161 0.83 Lumentum Holdings, Inc. 0.5% 15/12/2026 USD 300,000 318,881 1.00 MARA Holdings, Inc., 144A 0% 01/06/2031 USD 350,000 268,544 0.85 Merit Medical Systems, Inc., 144A 3% 01/02/2029 USD 200,000 243,388 0.77 Meritage Homes Corp., 144A 1.75% 15/05/2028 USD 300,000 284,524 0.90 Microchip Technology, Inc., 144A 0.75% 01/06/2030 USD 220,000 195,645 0.62 MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | • | | | | |
| Lumentum Holdings, Inc. 0.5% 15/12/2026 USD 300,000 318,881 1.00 MARA Holdings, Inc., 144A 0% 01/06/2031 USD 350,000 268,544 0.85 Merit Medical Systems, Inc., 144A 3% 01/02/2029 USD 200,000 243,388 0.77 Meritage Homes Corp., 144A 1.75% 15/05/2028 USD 300,000 284,524 0.90 Microchip Technology, Inc., 144A 0.75% 01/06/2030 USD 220,000 195,645 0.62 MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | | | | | |
| MARA Holdings, Inc., 144A 0% 01/06/2031 USD 350,000 268,544 0.85 Merit Medical Systems, Inc., 144A 3% 01/02/2029 USD 200,000 243,388 0.77 Meritage Homes Corp., 144A 1.75% 15/05/2028 USD 300,000 284,524 0.90 Microchip Technology, Inc., 144A 0.75% 01/06/2030 USD 220,000 195,645 0.62 MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | | | | | |
| Merit Medical Systems, Inc., 144A 3% 01/02/2029 USD 200,000 243,388 0.77 Meritage Homes Corp., 144A 1.75% 15/05/2028 USD 300,000 284,524 0.90 Microchip Technology, Inc., 144A 0.75% 01/06/2030 USD 220,000 195,645 0.62 MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | - | USD | 350,000 | | 0.85 |
| Microchip Technology, Inc., 144A 0.75% 01/06/2030 USD 220,000 195,645 0.62 MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | Merit Medical Systems, Inc., 144A 3% 01/02/2029 | USD | 200,000 | 243,388 | 0.77 |
| Microchip Technology, Inc., 144A 0.75% 01/06/2030 USD 220,000 195,645 0.62 MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | • | | | | |
| MicroStrategy, Inc., 144A 0.625% 15/09/2028 USD 150,000 266,263 0.84 Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | • | | | | |
| Middleby Corp. (The) 1% 01/09/2025 USD 250,000 269,712 0.85 | | USD | | | 0.84 |
| MKS Instruments, Inc., 144A 1.25% 01/06/2030 USD 325,000 304,296 0.96 | Middleby Corp. (The) 1% 01/09/2025 | USD | 250,000 | 269,712 | 0.85 |
| | MKS Instruments, Inc., 144A 1.25% 01/06/2030 | USD | 325,000 | 304,296 | 0.96 |

| Investments | Currency | Quantity/ Nominal Value | Market Value EUR | % of Net Assets |
|--|-------------------|----------------------------|------------------------|--------------------|
| Transferable securities and money market instruments dealt in on another re- | egulated market (| continued) | | |
| Convertible Bonds (continued) | | | | |
| United States of America (continued) | | | | |
| MP Materials Corp., 144A 3% 01/03/2030 | USD | 150,000 | 151,366 | 0.48 |
| NCL Corp. Ltd. 5.375% 01/08/2025 | USD | 150,000 | 206,905 | 0.65 |
| NextEra Energy Capital Holdings, Inc., 144A 3% 01/03/2027 | USD | 150,000 | 167,694 | 0.53 |
| ON Semiconductor Corp. 0.5% 01/03/2029 | USD | 425,000 | 387,825 | 1.22 |
| Parsons Corp., 144A 2.625% 01/03/2029 | USD | 250,000 | 283,825 | 0.89 |
| PG&E Corp. 4.25% 01/12/2027 | USD | 400,000 | 419,248 | 1.32 |
| PPL Capital Funding, Inc. 2.875% 15/03/2028 | USD | 150,000 | 151,040 | 0.48 |
| Progress Software Corp., 144A 3.5% 01/03/2030 | USD | 125,000 | 141,732 | 0.45 |
| Rivian Automotive, Inc. 4.625% 15/03/2029 | USD | 400,000 | 395,453 | 1.24 |
| Sarepta Therapeutics, Inc. 1.25% 15/09/2027 | USD | 225,000 | 238,336 | 0.75 |
| Shift4 Payments, Inc. 0% 15/12/2025 | USD | 150,000 | 196,378 | 0.62 |
| Snowflake, Inc., 144A 0% 01/10/2029 | USD | 400,000 | 461,057 | 1.45 |
| SoFi Technologies, Inc., 144A 1.25% 15/03/2029 | USD | 100,000 | 172,439 | 0.54 |
| Southern Co. (The) 3.875% 15/12/2025 | USD | 450,000 | 456,156 | 1.44 |
| Tyler Technologies, Inc. 0.25% 15/03/2026 | USD | 200,000 | 234,285 | 0.74 |
| Uber Technologies, Inc. 0.875% 01/12/2028 | USD | 375,000 | 399,367 | 1.26 |
| Varonis Systems, Inc., 144A 1% 15/09/2029 | USD | 196,000 | 177,911 | 0.56 |
| Ventas Realty LP, REIT 3.75% 01/06/2026 | USD | 250,000 | 273,710 | 0.86 |
| Vishay Intertechnology, Inc. 2.25% 15/09/2030 | USD | 500,000 | 431,819 | 1.36 |
| Wayfair, Inc. 3.25% 15/09/2027 | USD | 350,000 | 361,278 | 1.14 |
| Welltower OP LLC, REIT, 144A 3.125% 15/07/2029 | USD | 150,000 | 163,793 | 0.52 |
| Workiva, Inc., 144A 1.25% 15/08/2028 | USD | 150,000 | 153,714 | 0.48 |
| Zscaler, Inc. 0.125% 01/07/2025 | USD | 200,000 | 242,763 | 0.76 |
| | | _ | 17,016,349 | 53.55 |
| Total Convertible Bonds | | _ | 21,409,042 | 67.38 |
| Total Transferable securities and money market instruments dealt in on ano | ther regulated ma | arket | 21,409,042 | 67.38 |
| Total Investments | | _ | 31,364,884 | 98.71 |
| Cash | | <u></u> | 1,295,945 | 4.08 |
| Other assets/(liabilities) | | | (885,522) | (2.79) |
| Total net assets | | _ | 31,775,307 | 100.00 |

Lupus alpha Global Convertible Bonds Schedule of investments and other net assets (continued) As at 31 December 2024

Forward Currency Exchange Contracts

| | | | | | | Unrealised | |
|----------------|-----------------|--------------------|----------------|----------------------|---------------|-------------|----------|
| Currency | Amount | Currency | | | | Gain/(Loss) | % of Net |
| Purchased | Purchased | Sold | Amount Sold | Maturity Date | Counterparty | EUR | Assets |
| EUR | 1,533,160 | JPY | 250,000,000 | 21/02/2025 | Goldman Sachs | (4,613) | (0.01) |
| EUR | 6,982,842 | USD | 7,600,000 | 17/01/2025 | Deutsche Bank | (333,953) | (1.05) |
| EUR | 942,486 | USD | 1,000,000 | 21/02/2025 | Deutsche Bank | (18,814) | (0.06) |
| EUR | 660,511 | USD | 700,000 | 21/02/2025 | Goldman Sachs | (12,399) | (0.04) |
| EUR | 5,575,196 | USD | 5,900,000 | 21/02/2025 | J.P. Morgan | (96,474) | (0.30) |
| EUR | 8,847,161 | USD | 9,300,000 | 20/03/2025 | Deutsche Bank | (81,361) | (0.26) |
| Net Unrealised | Loss on Forward | Currency Ex | change Contrac | ets | | (547,614) | (1.72) |

The accompanying notes are an integral part of the Financial Statements

Lupus alpha Global Convertible Bonds Schedule of investments and other net assets (continued) As at 31 December 2024

Option Purchased Contracts

| | | | | Market Value | |
|-----------|--|----------|--------------|--------------|-----------------|
| Quantity | Security Description | Currency | Counterparty | EUR | % of Net Assets |
| • • • | | **** | | | 0.04 |
| 250 | First Majestic Silver Corp., Call, 7.000, 19/12/2025 | USD | J.P. Morgan | 19,748 | 0.06 |
| 500 | Plug Power, Inc., Call, 2.500, 20/06/2025 | USD | J.P. Morgan | 25,529 | 0.08 |
| 60 | Remy Cointreau SA, Call, 80.000, 20/06/2025 | EUR | J.P. Morgan | 4,500 | 0.02 |
| 150 | TripAdvisor, Inc., Call, 17.000, 16/01/2026 | USD | J.P. Morgan | 35,042 | 0.11 |
| Total Mai | ket Value on Option Purchased Contracts - Assets | | _ | 84,819 | 0.27 |

The accompanying notes are an integral part of the Financial Statements

Other information (unaudited)

Total Expense Ratio

The total expense ratio expresses the sum of costs and fees (excluding transaction costs and ongoing brokerage fees) as a percentage of the average sub-fund volume within a fiscal year.

The total expense ratio for the year ended 31 December 2024 was as follows:

For the period ended 30 June 2024

| Fund Name | Total expense ratio (%) |
|--|-------------------------|
| Lupus alpha Sustainable Smaller Euro Champions | |
| Class A | 1.68 |
| Class C | 1.17 |
| Class C | 1.17 |
| Lupus alpha Smaller German Champions | |
| Class A | 1.65 |
| Class C | 1.14 |
| Class CT | 1.15 |
| Lupus alpha Micro Champions | |
| Class A | 1.97 |
| Class C | 1.07 |
| Class CAV | 2.17 |
| Lupus alpha All Opportunities Fund | |
| Class A | 2.25 |
| Class C | 1.37 |
| Lupus alpha Global Convertible Bonds | |
| Class A Hedged | 1.36 |
| Class C Hedged | 0.76 |

Other information (unaudited) (continued)

Remuneration policy

Remuneration policy

The management company is subject to the regulations applying to its remuneration arrangements, in particular the rules set out in: (i) UCITS Directive 2014/91/EU, the ESMA final report on sound remuneration policies under the UCITS Directive and the AIFM Directive announced on 31 March 2016; (ii) AIFM Directive 2011/61/EU, as implemented in the Luxembourg AIFM Law of 12 July 2013 (current version), the ESMA Guidelines on sound remuneration policies under the AIFM announced on 11 February 2013; and

(iii) CSSF Circular 10/437 on Guidelines concerning remuneration policies in the financial sector. On this basis, the management company has adopted its own principles for remuneration, which include performance-related and entrepreneurial remuneration for employees. These remuneration principles are reviewed at least once a year.

The pre-determined remuneration principles establish a sustainable and effective risk management framework, are aligned with investor interests and discourage risk-taking that is inconsistent with the fund's risk profile or management regulations. The remuneration principles also ensure that all employees, including the management of the management company, are in line with the management company's strategic objectives and, in particular, they are also geared towards sustainable management of the management company, including further measures to avoid conflicts of interest.

This approach also focuses on:

- Remuneration paid to the Executive Board is determined by the Supervisory Board. For other employees, the employment contract regulates the parameters of the currently valid remuneration system.
- Employees and management receive appropriate fixed remuneration for their work; variable remuneration is not granted.
- Remuneration is determined taking into account the role of the individual employee, including the responsibility and complexity of their work, performance and local market conditions.

Further information on the calculation of remuneration, other benefits granted, the identity of the persons responsible for the allocation of remuneration and other benefits and other details of the management company's current remuneration policy are available on the management company's website at https://www.lupusalpha.de/nc/privatanleger/downloads/. Written copies of current remuneration policy are available free of charge from the management company upon request.

Information on employee remuneration in the event of outsourcing

The outsourcing company (Lupus alpha Asset Management AG) has published the following information:

| Total amount of employee remuneration paid in 2024 in EUR million | EUR 13.738 million |
|---|--------------------|
| of which fixed remuneration | 60.18 % |
| of which variable remuneration | 39.82 % |
| Remuneration paid directly out of the fund in EUR million | 0 |
| Number of employees incl. managing director | 93 |

Other information (unaudited) (continued)

Classification as per SFDR (EU 2019/2088)

Art. 6: Lupus alpha Smaller German Champions, Lupus alpha Micro Champions, Lupus alpha All Opportunities Fund and Lupus alpha Global Convertible Bonds

The investments underlying this financial product do not take into account the EU criteria for environmentally sustainable economic activities.

Art. 8: Lupus alpha Sustainable Smaller Euro Champions

The investments underlying this financial product do take into account the EU criteria for environmentally sustainable economic activities, but this is not their primary criteria for investing.

Regulatory information on the financial products referred to in Article 8 Paragraphs 1, 2 and 2a of Regulation (EU) 2019/2088 and Article 6 Paragraph 1 of Regulation (EU) 2020/852

Periodic disclosure for the financial products referred to in Article 8, paragraphs 1, 2 and 2a, of Regulation (EU) 2019/2088 and Article 6, first paragraph, of Regulation (EU) 2020/852

Sustainable investment
means an investment in an
economic activity that
contributes to an
environmental or social
objective, provided that the
investment does not
significantly harm any
environmental or social
objective and that the
investee companies follow
good governance practices.

The EU Taxonomy is a classification system laid down in Regulation (EU) 2020/852, establishing a list of environmentally sustainable economic activities. That Regulation does not lay down a list of socially sustainable economic activities. Sustainable investments with an environmental objective might be aligned with the Taxonomy or not.

Product name: Legal entity identifier: 529900LT6NXL4OKI2903 Lupus alpha Sustainable Smaller Euro Champions **Environmental and/or social characteristics** Did this financial product have a sustainable investment objective? Yes ⊠ No It made sustainable investments with It promoted Environmental/Social an environmental objective: % (E/S) characteristics and while it did not have as its objective a in economic activities that qualify as sustainable investment, it had a environmentally sustainable under the proportion of 79.10% of sustainable **EU Taxonomy** investments in economic activities that do not qualify with an environmental objective in as environmentally sustainable under the economic activities that qualify as **EU Taxonomy** environmentally sustainable under the **EU Taxonomy** with an environmental objective in economic activities that do not qualify as environmentally sustainable under the **EU Taxonomy** with a social objective It made sustainable investments with It promoted E/S characteristics, but a social objective:___% did not make any sustainable

investments.



Sustainability indicators

measure how the environmental or social characteristics promoted by the financial product are attained.

To what extent were the environmental and/or social characteristics promoted by this financial product met?

Environmental and social standards were given different weightings when implementing the fund's strategy. Investments were made in quality companies (small and mid-caps) while excluding unsustainable business models (e.g. mining of thermal coal or generation of nuclear power) and complying with minimum standards (e.g. violations of the UN Global Compact). ESG criteria were also integrated into the fundamental bottom-up analysis. The fund was not benchmark-oriented, nor did it replicate a benchmark. The fund did not use derivatives to fulfil the advertised social/environmental characteristics.

How did the sustainability indicators perform?

All investable companies were categorised according to environmental, social, ethical and governance criteria. The analysis included, among other things, social standards, environmental management, product portfolio and corporate governance. As part of a comprehensive negative screening, stocks that did not meet certain minimum standards were excluded. These applied to all securities (such as shares) and money market instruments in the portfolio:

Environmental:

- Mining of thermal coal > 5% of revenue
- Energy generation from thermal coal > 10% of revenue
- Production and distribution of nuclear power > 5% of revenue
- Products and services for the nuclear industry > 5% of revenue
- Extraction and exploration of oil sand and oil shale

Social:

- Violations of the UN Global Compact
- Violations of international human rights conventions and inadequate response/review by the company
- Violations of the ILO core labour standards in the company itself and in the supply chain, as well as inadequate reaction/follow-up by the company

Governance:

- Very serious controversies
- Violations of international anti-corruption conventions and inadequate response/follow-up by the company

Ethical:

- Production/distribution/services of cluster munitions, anti-personnel mines and other controversial weapons
- Production & distribution of military goods > 5% of revenue
- Tobacco production > 5% revenue

All companies that did not violate any of the exclusion criteria and were not excluded due to adverse impacts on sustainability factors (PAIs – see below) were generally investable.

Both the revenue thresholds mentioned, standards-based violations/controversies and the consideration of adverse impacts on sustainability factors (PAIs) were reviewed with the help of our external research provider MSCI and according to its methodology. Companies for which MSCI did not provide an analysis were reviewed internally. The information provided by MSCI was also reviewed internally, as the portfolio management usually has direct access

to the management of the companies under review and was able to critically analyse this information. In general, it can be said that the coverage of small and medium-sized companies in external ESG analyses is poorer than for large companies.

The fund complied with the exclusion criteria described above during the reporting period. Compliance with the exclusion criteria was permanently monitored by internal control systems.

...and compared to previous periods?

| Sustainability indicator | 01/01/2022- 31/12/2022 | 01/01/2023- 31/12/2023 | 01/01/2024- 31/12/2024 |
|---|---------------------------|---------------------------|---------------------------|
| Number of violations of exclusion criteria | 0.00 | 0.00 | 0.00 |
| Share of investments with E/S characteristics | 97.73% | 97.64% | 97.66% |
| Share of other investments | 2.27% | 2.36% | 2.34% |

We did not make any changes to the characteristics during the year compared to the previous period.

What were the objectives of the sustainable investments that the financial product partially made and how did the sustainable investment contribute to such objectives?

We consider an investment/company to be explicitly sustainable if its products and/or operational behaviour are aligned with at least one of the 17 Sustainable Development Goals (SDGs) (Aligned or Strongly Aligned), and at the same time its products and operational behaviour do not conflict with any of the other SDGs (Misaligned or Strongly Misaligned). The SDGs are the United Nations' sustainable development goals. Further information on these goals is available at https://sdgs.un.org/. We apply the MSCI ESG methodology when contribution to the SDGs. (Sustainable Impact Metrics: https://www.msci.com/our-solutions/esg-investing/impact-solutions). In addition. sustainable investments in the portfolio must have a minimum ESG rating of BB to ensure good corporate governance.

How did the sustainable investments that the financial product partially made not cause significant harm to any environmental or social sustainable investment objective?

In addition to the positive criterion described above, a number of negative criteria were also examined to ensure that the financial product was invested sustainably. It is crucial that the company's business practices, products and services are not contrary to any of the 17 SDGs (Misaligned or Strongly Misaligned). This is intended to ensure that sustainable investments do not significantly harm any of the environmental or social investment objectives.

In addition to the exclusion criteria described above for the entire investment fund, the following more extensive criteria apply for sustainable investments:

- No mining of thermal coal > 1% of revenue
- No tobacco production
- No revenues from tobacco > 5%

How were the indicators for adverse impacts on sustainability factors taken into account?

The assessment of adverse impacts on sustainability factors (PAIs) for sustainable investments follows the same approach as at the overall fund level (see below).

Were sustainable investments aligned with the OECD Guidelines for Multinational Enterprises and the UN Guiding Principles on Business and Human Rights? Details:

Investments that violate the UNGC principles or the OECD Guidelines for Multinational Enterprises are excluded. This applies to all shares in the portfolio.

The EU Taxonomy sets out a "do no significant harm" principle by whitch Taxonomy-aligned investments should not significantly harm EU Taxonomy objectives and is accompanied by specific Union criteria.

The "do no significant harm" principle applies only to those investments underlying the financial product that take into account the Union criteria for environmentally sustainable economic activities. The investments underlying the remaining portion of this financial product do not take into account the Union criteria for environmentally sustainable economic activities.

Any other sustainable investments must also not significantly harm any environmental or social objectives.



Principal adverse impacts

are the most significant negative impacts of investment decisions on sustainability factors relating to environmental, social and employee matters, respect for human rights, anticorruption and anti-bribery matters.

How did this financial product consider principal adverse impacts on sustainability factors?

The following adverse impacts on sustainability factors (PAIs) were explicitly taken into account in our investment process:

Environmental:

- Carbon footprint & carbon intensity
- Activities negatively affecting biodiversity-sensitive areas

Social:

- Violations of UN Global Compact principles and Organisation for Economic Cooperation and Development (OECD) Guidelines for Multinational Enterprises
- Exposure to controversial weapons (anti-personnel mines, cluster munitions, chemical weapons and biological weapons)

Governance:

- Board gender diversity
- Cases of insufficient action taken to address breaches of standards of anti-corruption and anti-bribery

If a company showed adverse effects on the sustainability factors mentioned, this generally led to exclusion. However, in order to give companies the opportunity to improve certain factors over time ("transition"), we entered into an engagement process with respect to the following factors, under certain conditions:

 Carbon footprint and carbon intensity (if both indicators were in the bottom quartile of the corresponding IVA industry). The underlying percentiles were calculated by the company itself based on the carbon data provided by MSCI. If MSCI data were not available, the company determined the data based on its own calculations.

or

 Lack of minimum gender diversity in management and control bodies (no women on the boards)

We would only be able to invest in the company if there were clear plans for improving these adverse impacts, or if such plans could be agreed with the company in direct dialogue. For these companies, we documented the plans, the changes that were targeted and the changes that were implemented. If the desired changes had not occurred or the company had not shown the agreed willingness, the position would have been sold as a last resort after several stages of escalation. However, this step was not necessary for any of the companies during the reporting period.

The above-described engagement could only be applied to one PAI at a time. If an investment in a company required engagement with more than one PAI, we refrained from investing.

The aforementioned PAIs were examined with the help of our external research provider MSCI. Companies for which MSCI did not provide an analysis were reviewed internally. The information provided by MSCI was also reviewed internally, as the portfolio management usually has direct access to the management of the companies under review and was able to critically analyse this information.



What were the top investments of this financial product?

The list includes the investments constituting the greatest proportion of investments of the financial product during the reference period which is:

01/01/2024-31/12/2024

| Largest investments | Sector | in % of assets | Country |
|---------------------------------|--|----------------|-------------|
| GEA Group AG DE0006602006 | Capital goods | 3.01% | Germany |
| Glanbia Plc IE0000669501 | Food, beverages & tobacco | 2.87% | Ireland |
| SPIE SA FR0012757854 | Commercial & professional services | 2.85% | France |
| Fugro NV NL00150003E1 | Capital goods | 2.83% | Netherlands |
| D'leteren S.A. BE0974259880 | Consumer discretionary: Distribution & retail | 2.63% | Belgium |
| Gerresheimer AG DE000A0LD6E6 | Pharmaceuticals, biotechnology and life sciences | 2.59% | Germany |
| IPSOS FR0000073298 | Media & entertainment | 2.55% | France |
| Fuchs SE DE000A3E5D64 | Raw materials | 2.35% | Germany |
| Qiagen N.V. NL0015001WM6 | Pharmaceuticals, biotechnology and life sciences | 2.32% | Germany |
| Huhtamaki Oyj Fl0009000459 | Raw materials | 2.30% | Finland |
| Arcadis N.V. NL0006237562 | Commercial & professional services | 2.28% | Netherlands |
| Teleperformance SA FR0000051807 | Commercial & professional services | 2.28% | France |
| Societe BIC SA FR0000120966 | Commercial & professional services | 2.23% | France |
| Nexans SA FR0000044448 | Capital goods | 2.16% | France |
| Andritz AG AT0000730007 | Capital goods | 2.13% | Austria |




Asset allocation describes the share of investments in specific assets.

What was the proportion of sustainability-related investments?

Sustainability-related investments are investments that contribute to the achievement of environmental and/or social characteristics as part of the investment strategy. The share was 97.66%.

What was the asset allocation?



#1 Aligned with E/S characteristics includes the investments of the financial product used to attain the environmental or social characteristics promoted by the financial product.

#2 Other includes the remaining investments of the financial product which are neither aligned with the environmental or social characteristics, nor are qualified as sustainable investments.

The category **#1 Aligned with E/S characteristics** covers:

- The sub-category #1A Sustainable covers environmentally and socially sustainable investments.
- The sub-category #1B Other E/S characteristics covers investments aligned with the environmental or social characteristics that do not qualify as sustainable investments.

In which economic sectors were the investments made?

The following table shows the economic sectors and sub-sectors in which the financial product was invested during the reporting period. Investments were allocated to the sectors and sub-sectors based on data from external research providers and internal research.

In addition, 16.48% of investments were made in the fossil fuels sector during the reporting period. Data from the external research provider MSCI ESG Research was used to calculate the share of investments in fossil fuel sectors and sub-sectors. The share includes companies that generate revenues in the area of fossil fuels, including the extraction, processing, storage and transportation of petroleum products, natural gas, thermal and metallurgical coal.

The calculations are based on the average of the data on the four quarterly reporting dates (28/03/2024, 28/06/2024, 30/09/2024, 30/12/2024).

| Sector | Share |
|--|--------|
| Capital goods | 23.17% |
| Commercial and professional services | 12.68% |
| Raw materials | 10.34% |
| Pharmaceuticals, biotechnology and life sciences | 7.06% |
| Software & services | 6.27% |
| Consumer goods & clothing | 4.99% |
| Media & entertainment | 4.23% |
| Insurance | 4.10% |
| Consumer services | 3.77% |
| Semiconductors and semiconductor equipment | 3.04% |
| Food, beverages & tobacco | 2.96% |
| Energy | 2.73% |
| Consumer discretionary: Distribution and retail | 2.63% |
| Healthcare: Equipment & services | 2.35% |
| Hardware & equipment | 1.59% |
| Banks | 1.52% |
| Consumer staples: Distribution and retail | 1.07% |
| Motor vehicles and components | 1.04% |
| Transportation | 0.88% |
| Financial services | 0.51% |
| Household articles and personal care products | 0.48% |

Taxonomy-aligned activities are expressed as a share of:

- turnover reflects the "greenness" of investee companies today
- capital expenditure
 (CapEx) shows the green
 investments made by
 investee companies,
 relevant for a transition to
 a green economy.
- operational expenditure (OpEx) reflecting green operational activities of investee companies.

To comply with the EU Taxonomy, the criteria for fossil gas include limitations on emissions and switching to fully renewable power or low-carbon fuels by the end of 2035. For nuclear energy, the criteria include comprehensive safety and waste management rules.

Enabling activities directly enable other activities to make a substantial contribution to an environmental objective.

Transitional activities are activities for which low-carbon alternatives are not yet available and among others have greenhouse gas emission levels corresponding to the best performance.



To what extent were the sustainable investments with an environmental objective aligned with the EU Taxonomy?

The table shows the share of Taxonomy-aligned sustainable investments of the fund, expressed in terms of turnover, capital expenditure (CapEx) and operating expenditure (OpEx) as at 30/12/2024:

| Based on turnover | 7.65% |
|-------------------|-------|
| Based on CapEx | 7.73% |
| Based on OpEx | 6.65% |

The share of Taxonomy-aligned investments of total fund assets as at 30/12/2024 was:

| Based on turnover | 9.61% |
|-------------------|-------|
| Based on CapEx | 9.40% |
| Based on OpEx | 8.59% |


Many companies are reporting on the alignment of their activities with the EU Taxonomy for the first time. In order to meet transparency requirements, we collect and consolidate all Taxonomy data available to us from our data provider. However, it should be noted that the quality of the data is still limited due to the complexity and novelty of the topic: Errors can occur in both corporate reporting and data integration by providers.

Did the financial product invest in fossil gas and/or nuclear energy related activities complying with the EU Taxonomy?

| \boxtimes | Yes: | | | |
|-------------|-------------|---------------|-------------|-------------------|
| | \boxtimes | In fossil gas | \boxtimes | In nuclear energy |
| | No | | | |

| | Taxonomy-aligned | Taxonomy-aligned activities in |
|--------------------------------------|---------------------------|--------------------------------|
| | activities in the area of | the area of nuclear energy |
| | fossil gas | |
| Based on turnover | 0.00% | 0.01% |
| Based on capital expenditure (CapEx) | 0.01% | 0.01% |
| Based on operating expenses (OpEx) | 0.00% | 0.00% |

The graphs below show in green the percentage of investments that were aligned with the EU Taxonomy. As there is no appropriate methodology to determine the taxonomy-alignment of sovereign bonds*, the first graph shows the Taxonomy alignment in relation to all the investments of the financial product including sovereign bonds, while the second graph shows the Taxonomy alignment only in relation to the investments of the financial product other than sovereign bonds.



What was the share of investments made in transitional and enabling activities?¹

The table shows the share of investments in total fund assets that went into transition and enabling activities, expressed in terms of turnover, capital expenditure (CapEx) and operating expenditure (OpEx):

| | Transitional activities | Enabling activities |
|--------------------------------------|-------------------------|---------------------|
| Based on turnover | 2.16% | 6.03% |
| Based on capital expenditure (CapEx) | 2.65% | 3.78% |
| Based on operating expenses (OpEx) | 2.05% | 5.28% |

How did the percentage of investments that were aligned with the EU Taxonomy compare with previous reference periods?

No share of investments that were aligned with the EU Taxonomy was recorded for the previous period.

¹ Fossil gas and/or nuclear related activities will only comply with the EU Taxonomy where they contribute to limiting climate change ("climate change mitigation") and do not significantly harm any EU Taxonomy objective - see explanatory note in the left hand margin. The full criteria for fossil gas and nuclear energy economic activities that comply with the EU Taxonomy are laid down in Commission Delegated Regulation (EU) 2022/1214.

are sustainable investments with an environmental objective that do not take into account the criteria for environmentally sustainable economic activities under Regulation (EU)2020/852.



What was the share of sustainable investments with an environmental objective not aligned with the EU Taxonomy?

As at 30/12/2024, the share of the fund's sustainable investments with an environmental objective not aligned with the EU Taxonomy was 23.85%.



What was the share of socially sustainable investments?

The share of socially sustainable investments as at 30 December 2024 was 47.60%.



What investments were included under "other", what was their purpose and were there any minimum environmental or social safeguards?

Bank deposits were categorised under "#2 Other investments". These were used for liquidity management. There was no minimum level of environmental or social protection.



What actions have been taken to meet the environmental and/or social characteristics during the reference period?

Compliance with the defined ESG criteria was ensured consistently and was or is continuously monitored by both compliance and portfolio management. In terms of compliance, we work with the compliance manager of SimCorpDimensions. An internal ESG tool has been developed for the front office, which portfolio management can use to check the compliance of its investments with ESG criteria, analyse individual securities in detail and evaluate aggregated portfolio key performance indicators (KPIs). This tool is based on data from MSCI. For issuers not covered by MSCI, independent assessments were carried out with regard to the relevant ESG criteria. If an internal assessment was not possible in these cases, we refrained from making the investment. This ensured that investments were only made in companies that complied with the environmental and social criteria we had set. If the investment conditions for a company changed for the worse (e.g. due to a new controversy that the company had not adequately addressed), we reacted immediately and sold the position in a market-friendly manner. In addition, we took into account the principal adverse impacts on the sustainability factors (PAIs) in the investment process.

Based on our methodology for considering the PAIs, we entered into a formal engagement process with selected portfolio companies in the 2024 reporting year.